Form 10-Q - Quarterly report [Sections 13 or 15(d)]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: September 30, 2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from: _______ to _______

Commission File Number: 001-32288

NEPHROS, INC.

(Exact name of registrant as specified in its charter)

delaware

13-3971809

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

380 Lackawanna Place

South Orange, NJ

07079

(Address of principal executive offices)

(Zip Code)

(201) 343-5202

Registrant’s telephone number, including area code

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol		Name of exchange on which registered
Common stock, par value $0.001 per share		NEPH		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ YES ☐ NO

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ YES ☐ NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller reporting company ☒
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ YES ☒ NO

As of November 6, 2023, 10,484,932 shares of the registrant’s common stock, $0.001 par value per share, were outstanding.

NEPHROS, INC. AND SUBSIDIARIES

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION	3

Item 1. Financial Statements (unaudited).	3

CONSOLIDATED BALANCE SHEETS – September 30, 2023 and December 31, 2022	3

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS – Three and nine months ended September 30, 2023 and 2022	4

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY – Three and nine months ended September 30, 2023 and 2022	5

CONSOLIDATED STATEMENTS OF CASH FLOWS – Nine months ended September 30, 2023 and 2022	7

NOTES TO CONSOLIDATED INTERIM FINANCIAL STATEMENTS	8

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.	19

Item 3. Quantitative and Qualitative Disclosures About Market Risk.	27

Item 4. Controls and Procedures.	28

PART II - OTHER INFORMATION	28

Item 1A. Risk Factors	28

Item 6. Exhibits	28

SIGNATURES	29

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

NEPHROS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share amounts)

(Unaudited)

	September 30, 2023			December 31, 2022
ASSETS
Current assets:
Cash and cash equivalents	$	4,622		$	3,634
Accounts receivable, net		1,443			1,286
Inventory		2,268			3,153
Prepaid expenses and other current assets		173			188
Total current assets		8,506			8,261
Property and equipment, net		88			116
Lease right-of-use assets		750			984
Intangible assets, net		392			423
Goodwill		759			759
License and supply agreement, net		301			402
Other assets		123			54
TOTAL ASSETS	$	10,919		$	10,999

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current portion of secured note payable	$	-		$	71
Accounts payable		805			740
Accrued expenses		712			285
Current portion of lease liabilities		311			316
Total current liabilities		1,828			1,412
Equipment financing, net of current portion		-			1
Lease liabilities, net of current portion		469			705
TOTAL LIABILITIES		2,297			2,118

COMMITMENTS AND CONTINGENCIES (Note 14)		-			-

STOCKHOLDERS’ EQUITY

Preferred stock, $.001 par value; 5,000,000 shares authorized at September 30, 2023 and December 31, 2022; no shares issued and outstanding at September 30, 2023 and December 31, 2022.		-			-
Common stock, $.001 par value; 40,000,000 shares authorized at September 30, 2023 and December 31, 2022; 10,484,932 and 10,297,429 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively.		10			10
Additional paid-in capital		152,364			148,413
Accumulated deficit		(143,752	)		(142,831	)
Subtotal		8,622			5,592
Noncontrolling interest		-			3,289
TOTAL STOCKHOLDERS’ EQUITY		8,622			8,881
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	10,919		$	10,999

The accompanying notes are an integral part of these unaudited consolidated interim financial statements.

NEPHROS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except share and per share amounts)

(Unaudited)

	2023			2022			2023			2022
	Three Months Ended September 30,						Nine Months Ended September 30,
	2023			2022			2023			2022
Net revenue:
Product revenues	$	3,713		$	2,399		$	10,912		$	7,387
Royalty and other revenues		29			10			72			30
Total net revenues		3,742			2,409			10,984			7,417
Cost of goods sold		1,548			1,647			4,600			4,195
Gross margin		2,194			762			6,384			3,222
Operating expenses:
Selling, general and administrative		2,137			1,743			6,500			5,806
Research and development		205			252			665			896
Depreciation and amortization		55			48			163			162
Total operating expenses		2,397			2,043			7,328			6,864
Operating loss from continuing operations		(203	)		(1,281	)		(944	)		(3,642	)
Other (expense) income:
Interest expense		-			(4	)		(1	)		(17	)
Interest income		11			4			36			7
Other income (expense), net		10			31			(12	)		94
Total other expense:		21			31			23			84
Loss from continuing operations		(182	)		(1,250	)		(921	)		(3,558	)
Net loss from discontinued operations		-			(1,904	)		-			(2,700	)
Net loss		(182	)		(3,154	)		(921	)		(6,258	)
Less: Undeclared deemed dividend attributable to noncontrolling interest		-			(77	)		-			(206	)
Net loss attributable to Nephros, Inc. shareholders	$	(182	)	$	(3,231	)	$	(921	)	$	(6,464	)
Net loss per common share, basic and diluted from continuing operations		(0.02	)		(0.12	)		(0.09	)		(0.35	)
Net loss per common share, basic and diluted from discontinued operations		-			(0.18	)		-			(0.26	)
Net loss per common share, basic and diluted		(0.02	)		(0.30	)		(0.09	)		(0.61	)
Net loss per common share, basic and diluted, attributable to continuing noncontrolling interest		-			(0.01	)		-			(0.02	)
Net loss per common share, basic and diluted, attributable to Nephros, Inc, shareholders	$	(0.02	)	$	(0.31	)		(0.09	)	$	(0.63	)
Weighted average common shares outstanding, basic and diluted		10,460,866			10,303,818			10,352,108			10,278,258

Comprehensive loss:
Net loss	$	(182	)	$	(3,154	)	$	(921	)	$	(6,258	)
Other comprehensive loss, foreign currency translation adjustments, net of tax		-			-			-			(3	)
Comprehensive loss		(182	)		(3,154	)		(921	)		(6,261	)
Comprehensive loss attributable to noncontrolling interest		-			(77	)		-			(206	)
Comprehensive loss attributable to Nephros, Inc. shareholders	$	(182	)	$	(3,231	)	$	(921	)	$	(6,467	)

The accompanying notes are an integral part of these unaudited consolidated interim financial statements.

NEPHROS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY

(In thousands, except share amounts)

(Unaudited)

	Shares		Amount		Capital		Income		Deficit			Subtotal			Interest			Equity
	Three and nine months ended September 30, 2023
	Common Stock				Additional Paid-in		Accumulated Other Comprehensive		Accumulated						Noncontrolling			Total Stockholders’
	Shares		Amount		Capital		Income		Deficit			Subtotal			Interest			Equity
Balance, December 31, 2022		10,297,429	$	10	$	148,413	$	-	$	(142,831	)	$	5,592		$	3,289		$	8,881
Net loss		-		-		-		-		(306	)		(306	)		-			(306	)
Change in non-controlling interest		-		-		3,262		-		-			3,262			(3,262	)		-
Stock-based compensation		-		-		346		-		-			346			(27	)		319
Balance, March 31, 2023		10,297,429	$	10	$	152,021	$	-	$	(143,137	)	$	8,894		$	-		$	8,894

Net loss		-	$	-	$	-	$	-	$	(433	)	$	(433	)	$	-		$	(433	)
Stock-based compensation		-		-		194		-		-			194			-			194
Balance, June 30, 2023		10,297,429	$	10	$	152,215	$	-	$	(143,570	)	$	8,655		$	-		$	8,655
Net loss		-		-		-		-	$	(182	)	$	(182	)		-		$	(182	)
Restricted stock vesting		187,503		-		-		-		-			-			-			-
Stock-based compensation		-		-		149		-		-			149			-			149
Balance, September 30, 2023		10,484,932	$	10	$	152,364	$	-	$	(143,752	)	$	8,622		$	-		$	8,622

	Three and nine months ended September 30, 2022

	Common Stock				Additional Paid-in		Accumulated Other Comprehensive			Accumulated						Non controlling		Total Stockholders’
	Shares		Amount		Capital		Income			Deficit			Subtotal			Interest		Equity
Balance, December 31, 2021		10,198,712	$	10	$	147,346	$	64		$	(135,725	)	$	11,695		$	3,054	$	14,749
Net loss		-		-		-		-			(1,967	)		(1,967	)		-		(1,967	)
Change in non-controlling interest		-		-		-		-			-			-			188		188
Net unrealized losses on foreign currency translation, net of tax		-		-		-		(3	)		-			(3	)		-		(3	)
Exercise of warrants		60,374		-		163		-			-			163			-		163
Stock-based compensation		-		-		272		-			-			272			-		272
Balance, March 31, 2022		10,259,086	$	10	$	147,781	$	61		$	(137,692	)	$	10,160		$	3,242	$	13,402

Net loss		-	$	-	$	-	$	-		$	(1,137	)	$	(1,137	)	$	-	$	(1,137	)
Restricted stock vesting		44,732		-		-		-			-			-			-		-
Elimination of cumulative translation adjustment, upon closing of wholly owned foreign subsidiary		-		-		-		(61	)		-			(61	)		-		(61	)
Stock-based compensation		-		-		259		-			-			259			18		277
Balance, June 30, 2022		10,303,818	$	10	$	148,040	$	-		$	(138,829	)	$	9,221		$	3,260	$	12,481

Net loss		-		-		-		-			(3,154	)		(3,154	)		-		(3,154	)
Stock-based compensation		-		-		235		-			-			235			19		254
Balance, September 30, 2022		10,303,818	$	10	$	148,275	$	-		$	(141,983	)	$	6,302		$	3,279	$	9,581

The accompanying notes are an integral part of these unaudited consolidated interim financial statements.

NEPHROS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

	2023			2022
	Nine Months Ended September 30,
	2023			2022
OPERATING ACTIVITIES:
Net loss	$	(921	)	$	(6,258	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation of property and equipment		29			82
Amortization of intangible assets, license and supply agreement and finance lease right-of-use asset		134			214
Stock-based compensation, including stock options and restricted stock		662			803
Inventory obsolescence charge		106			773
Provision for bad debt expense		14			(1	)
Impairment of assets held for sale		-			1,395
Gain on foreign currency transactions		-			(60	)
Decrease (increase) in operating assets:
Accounts receivable		(171	)		269
Inventory		778			429
Prepaid expenses and other current assets		15			28
Right-of-use assets		234			262
Other assets		(69	)		26
(Decrease) increase in operating liabilities:
Accounts payable		65			(555	)
Accrued expenses		425			(174	)
Lease liabilities		(237	)		(272	)
Net cash provided by (used in) operating activities		1,064			(3,039	)
INVESTING ACTIVITIES:
Purchase of property and equipment		-			(137	)
Net cash used in investing activities		-			(137	)
FINANCING ACTIVITIES:
Proceeds from sale of subsidiary preferred shares to noncontrolling interest		-			188
Principal payments on finance lease liability		(4	)		(3	)
Principal payments on equipment financing		(1	)		(2	)
Payments on secured note payable		(71	)		(201	)
Proceeds from exercise of warrants		-			163
Net cash provided by (used in) financing activities		(76	)		145
Effect of exchange rates on cash and cash equivalents		-			(2	)
Net increase (decrease) in cash and cash equivalents		988			(3,033	)
Cash and cash equivalents, beginning of period		3,634			6,973
Cash and cash equivalents, end of period	$	4,622		$	3,940
Supplemental disclosure of cash flow information
Cash paid for interest	$	6		$	17
Supplemental disclosure of noncash investing and financing activities
Right-of-use asset obtained in exchange for operating lease liability	$	-		$	69

The accompanying notes are an integral part of these unaudited consolidated interim financial statements.

NEPHROS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)

Note 1 – Organization and Nature of Operations

Nephros, Inc. (“Nephros” or the “Company”) was incorporated under the laws of the State of Delaware on April 3, 1997. The Company was founded by health professionals, scientists and engineers affiliated with Columbia University to develop advanced end stage renal disease (“ESRD”) therapy technology and products.

Beginning in 2009, Nephros introduced high performance liquid purification filters to meet the demand for water purification in certain medical markets. The Company’s filters, generally classified as ultrafilters, are primarily used in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, and in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate. The Company also develops and sells water filtration products for commercial applications, focusing on the hospitality and food service markets.

On October 4, 2022, the Company entered into a definitive asset purchase agreement with a third party for the sale of substantially all of the Company’s Pathogen Detection Systems (“PDS”) business, which had been previously reported as a separate reportable operating segment. As a result of the sale of the PDS business, we completely exited the PDS business. As a result, we determined that our PDS business had met the criteria for discontinued operations as of September 30, 2022. We no longer separately report the PDS business as a separate reportable segment in our financial statements including in this Quarterly Report for any of the periods presented.

In July 2018, the Company formed a subsidiary, Specialty Renal Products, Inc. (“SRP”), to drive the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. After SRP’s formation, the Company assigned to SRP all of the Company’s rights to three patents relating to the Company’s hemodiafiltration technology, which were carried at zero book value. On March 9, 2023, the SRP Stockholders approved a plan of dissolution to wind down SRP’s operations, liquidate SRP’s remaining assets and dissolve SRP. Pursuant to such plan, SRP filed a certificate of dissolution with the State of Delaware on April 13, 2023. As a result of the SRP Stockholders’ approval of the plan of dissolution and provisions therein and after satisfying all of SRP’s liabilities, there are no assets available for distribution to the holders of any of SRP’s capital stock, including its Series A Preferred Stock. As such, the value recorded to non-controlling interest was written to zero and the impact reclassified to the Company’s additional paid-in capital as the Company retained control of SRP.

The Company’s primary U.S. facility is located at 380 Lackawanna Place, South Orange, New Jersey 07079. This location houses the Company’s corporate headquarters, research, manufacturing, and distribution facilities.

Note 2 – Basis of Presentation and Liquidity

Interim Financial Information

The accompanying unaudited consolidated interim financial statements have been prepared in accordance with generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 and Article 10 of Regulation S-X. The consolidated balance sheet as of December 31, 2022 was derived from the Company’s audited financial statements. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. Results as of and for the nine months ended September 30, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.

The consolidated interim financial statements and notes thereto should be read in conjunction with the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.

Segment Reporting

The Company operates in only one business segment from which the Company’s chief operating decision maker evaluates the financial performance of the Company.

Consolidation

The accompanying consolidated financial statements include the accounts of Nephros, Inc. and its subsidiaries, including the Company’s wholly owned subsidiary Nephros International, which was dissolved during the quarter ended June 30, 2022, and SRP, which was dissolved pursuant to a plan of dissolution adopted by its stockholders on March 9, 2023 and the subsequent filing of a certificate of dissolution with the State of Delaware on April 13, 2023. All intercompany accounts and transactions were eliminated in the preparation of the accompanying consolidated financial statements.

Use of Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amount of revenues and expenses, during the reporting period. Actual results could differ materially from those estimates. Included in these estimates are assumptions about the collection of accounts receivable, value of inventories, useful life of fixed assets and intangible assets, the assessment of expected cash flows used in evaluating goodwill and other long-lived assets, and assumptions used in determining stock compensation such as expected volatility and risk-free interest rate.

Liquidity

In February 2022, pursuant to a First Amendment to Series A Preferred Stock Purchase Agreement (the “Amendment”) among SRP and the holders of SRP’s outstanding shares of Series A Preferred Stock, SRP issued and sold an additional 100,003 shares of its Series A Preferred Stock at a price of $5.00 per share, resulting in total gross proceeds of $500,015. See “Note 12 – Stockholders’ Equity – Noncontrolling Interest,” below. In addition to the funds provided by the sale of these additional shares of Series A Preferred Stock, the Company and SRP also maintained a loan agreement under which the Company loaned $1.3 million to SRP, of which $1.0 million had been loaned during the year ended December 31, 2020. These loaned funds were used to fund SRP’s operating activities through the FDA 510(k) clearance process of SRP’s second-generation hemodiafiltration system, which was initially submitted to the FDA on February 24, 2021, and which received 510(k) clearance on May 13, 2022. In connection with SRP’s plan of dissolution and pursuant to an agreement between the Company and SRP entered into on May 24, 2023, SRP assigned substantially all of its remaining assets to the Company in satisfaction of the entire loan balance. Accordingly, as of September 30, 2023, there was no outstanding balance of this loan.

The Company has sustained operating losses every quarter through December 31, 2022, generating an accumulated deficit of $143.8 million as of September 30, 2023. Throughout 2023, however, the Company’s operating cash flows have been positive due to increased sales, improved gross margins, careful expense management, and the dispositions of the PDS and SRP businesses. These actions resulted in the Company generating cash from operations of approximately $1.1 million through the nine months ended September 30, 2023. Based on these positive cash flows, the Company believes that its cash balances are sufficient to fund its current operating plan through at least the next 12 months from the date of issuance of the accompanying consolidated financial statements. However, in the event that the Company’s operating results do not meet its expectations, the Company may need to further reduce discretionary expenditures such as headcount, R&D projects, and other variable costs.

Recently Adopted Accounting Pronouncements

In October 2021, the FASB issued ASU 2021-08, “Accounting for Contract Assets and Contract Liabilities from Contracts with Customers,” which requires that an entity recognize contract assets and contract liabilities acquired in a business combination in accordance with Accounting Standards Codification (“ASC”) 606. The guidance is effective for the Company beginning in the first quarter of fiscal year 2023 and should be applied prospectively. The Company adopted this guidance as of January 1, 2023 and the guidance did not have an impact on its consolidated financial statements.

Concentration of Credit Risk

The Company deposits its cash in financial institutions. At times, such deposits may be in excess of insured limits. To date, the Company has not experienced any impairment losses on its cash. The Company also limits its credit risk with respect to accounts receivable by performing credit evaluations when deemed necessary.

Major Customers

For the three months ended September 30, 2023, and 2022, the following customers accounted for the following percentages of the Company’s revenues, respectively:

Customer	2023			2022
A		35	%		33	%
B		13	%		4	%
Total		48	%		37	%

For the nine months ended September 30, 2023, and 2022, the following customers accounted for the following percentages of the Company’s revenues, respectively:

Customer	2023			2022
A		24	%		24	%
B		11	%		10	%
Total		35	%		34	%

As of September 30, 2023, and December 31, 2022, the following customers accounted for the following percentages of the Company’s accounts receivable, respectively:

Customer	2023			2022
C		15	%		10	%
A		14	%		21	%
B		4	%		10	%
Total		33	%		41	%

Accounts Receivable

The Company recognizes an allowance that reflects a current estimate of credit losses expected to be incurred over the life of a financial asset, including trade receivables. The Company continuously monitors collections and payments from its customers and maintains a provision for estimated credit losses. The Company determines its allowance for doubtful accounts by considering a number of factors, including the length of time balances are past due, the Company’s previous loss history, the customer’s current ability to pay its obligations to the Company and the expected condition of the general economy and the industry as a whole. The Company writes off accounts receivable when they are determined to be uncollectible. The allowance for doubtful accounts was approximately $14,000 as of September 30, 2023. There was no allowance for doubtful accounts as of December 31, 2022.

Depreciation Expense

Depreciation related to equipment utilized in the manufacturing process is recognized in cost of goods sold on the consolidated statements of operations and comprehensive loss. For the three and nine months ended September 30, 2023, depreciation expense was approximately $1,000 and $3,000, respectively. For the three and nine months ended September 30, 2022, depreciation expense was approximately $3,000 and $19,000, respectively.

Note 3 – Revenue Recognition

The Company recognizes revenue related to product sales when product is shipped via external logistics providers and the other criteria of ASC 606 are met. Product revenue is recorded net of returns and allowances. There was no allowance for sales returns for the three and nine months ended September 30, 2023, or 2022. In addition to product revenue, the Company recognizes revenue related to royalty and other agreements in accordance with the five-step model in ASC 606. Other revenues recognized for the three and nine months ended September 30, 2023 were approximately $29,000 and $72,000, respectively. Other revenues recognized for the three and nine months ended September 30, 2022 were approximately $10,000 and $30,000, respectively.

Other Revenue – Other revenues are derived from sales of services to customers, which primarily include installation, training and testing on products and equipment sold to certain customers.

Note 4 – Discontinued Operations

In accordance with ASC 205-20, “Presentation of Financial Statements: Discontinued Operations”, a disposal of a component of an entity or a group of components of an entity (disposal group) is required to be reported as discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results when the disposal group meets the criteria to be classified as held-for-sale. The consolidated statements of operations reported for current and prior periods report the results of operations of the discontinued operations, including the impairment loss recognized as a component of net income (loss) separate from the net income (loss) from continuing operations.

All discontinued operations relate to the Company’s previously reported PDS segment, for the three and nine months ended September 30, 2022.

	Three Months Ended			Nine Months Ended
	September 30, 2022			September 30, 2022
		(in thousands)			(in thousands)
Total net revenues	$	79		$	141
Gross loss		(149	)		(211	)
Research and development expenses		192			556
Depreciation and amortization expense		7			21
Selling, general and administrative expenses		161			517
Total operating expenses		360			1,094
Operating loss from discontinued operations		(509	)		(1,305	)
Impairment of assets held for sale		(1,395	)		(1,395	)
Loss from discontinued operations	$	(1,904	)	$	(2,700	)

The following items related to discontinued operations were included in the condensed consolidated statement of cash flows:

	For the nine months ended,
	September 30, 2022
		(in thousands)
Depreciation	$	42
Amortization		82
Stock compensation		66
Impairment of assets held-for-sale		1,395
Operating lease right-of-use assets		33
Purchases of property and equipment		(34	)

Note 5 – Fair Value Measurements

The Company measures certain financial instruments and other items at fair value.

To determine the fair value, the Company uses the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability.

To measure fair value, the Company uses the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and also includes instruments for which the determination of fair value requires significant judgment or estimation.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level of classification for each reporting period.

At September 30, 2023 and December 31, 2022, the Company’s cash equivalents consisted of money market funds and certificates of deposit that can be withdrawn before maturity. The Company values its cash equivalents using observable inputs that reflect quoted prices for securities with identical characteristics and classify the valuation techniques that use these inputs as Level 1.

At September 30, 2023 and December 31, 2022, the fair value measurements of the Company’s assets and liabilities measured on a recurring basis were as follows:

	Fair Value Measurements at Reporting Date Using
	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
	(in thousands)
September 30, 2023
Cash	$	1,320		$		$
Money market funds		1,802
Certificate of deposit		1,500
Cash and cash equivalents	$	4,622	$	-	$	-

December 31, 2022
Cash	$	1,598		$		$
Money market funds		2,036
Cash and cash equivalents	$	3,634	$	-	$	-

Assets and Liabilities Not Measured at Fair Value on a Recurring Basis

The carrying amounts of accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term maturity of these instruments.

The carrying amounts of the secured long-term note payable, lease liabilities and equipment financing approximate fair value as of September 30, 2023 and December 31, 2022 because those financial instruments bear interest at rates that approximate current market rates for similar agreements with similar maturities and credit.

Note 6 – Inventory

Inventory is stated at the lower of cost or net realizable value using the first-in, first-out method and consists of raw materials and finished goods. The Company’s inventory components as of September 30, 2023 and December 31, 2022, were as follows:

	September 30, 2023		December 31, 2022
		(in thousands)
Finished goods	$	1,895	$	2,709
Raw materials		373		422
Work in process		-		22
Total inventory	$	2,268	$	3,153

Note 7 – Intangible Assets and Goodwill

Intangible Assets

Intangible assets as of September 30, 2023 and December 31, 2022 are set forth in the table below. Gross carrying values and accumulated amortization of the Company’s intangible assets by type are as follows:

	September 30, 2023							December 31, 2022
	Cost		Accumulated Amortization			Net		Cost		Accumulated Amortization			Net
		(in thousands)
Tradenames, service marks and domain names	$	50	$	(47	)	$	3	$	50	$	(40	)	$	10
Customer relationships		540		(151	)		389		540		(127	)		413
Total intangible assets	$	590	$	(198	)	$	392	$	590	$	(167	)	$	423

The Company recognized amortization expense of approximately $11,000 for each of the three months ended September 30, 2023 and September 30, 2022. All were recognized in selling, general and administrative expenses on the accompanying consolidated statement of operations and comprehensive loss.

The Company recognized amortization expense of approximately $31,000 for each of the nine months ended September 30, 2023 and September 30, 2022. All were recognized in selling, general and administrative expenses on the accompanying condensed statement of operations and comprehensive loss.

As of September 30, 2023, future amortization expense for each of the next five years is (in thousands):

Fiscal Years
2023 (excluding the nine months ended September 30, 2023)	$	11
2024		32
2025		32
2026		32
2027		32
2028		32

The Company recognized approximately $1.0 million in intangible asset impairment charges during the three and nine months ended September 30, 2022, related to the fair value of assets held for sale. (See Note 4 –Discontinued Operations).

Goodwill

Goodwill has a carrying value on the Company’s consolidated balance sheets of approximately $0.8 million at September 30, 2023 and December 31, 2022.

Note 8 – License and Supply Agreement, net

On April 23, 2012, the Company entered into a License and Supply Agreement (as thereafter amended, the “License and Supply Agreement”) with Medica S.p.A. (“Medica”), an Italy-based medical product manufacturing company, for the marketing and sale of certain filtration products based upon Medica’s proprietary Medisulfone ultrafiltration technology in conjunction with the Company’s filtration products, and for an exclusive supply arrangement for the filtration products. Under the License and Supply Agreement, Medica granted to the Company an exclusive license, with right of sublicense, to market, promote, distribute, offer for sale and sell the filtration products worldwide, with certain limitations on territory, during the term of the License and Supply Agreement. In addition, the Company granted to Medica an exclusive license under the Company’s intellectual property to make the filtration products during the term of the License and Supply Agreement. The filtration products covered under the License and Supply Agreement includes both certain products based on Medica’s proprietary Versatile microfiber technology and certain filtration products based on Medica’s proprietary Medisulfone ultrafiltration technology. The License and Supply Agreement expires on December 31, 2025, unless earlier terminated by either party in accordance with its terms. The Company is in active discussions to extend the License and Supply Agreement and expects to complete this extension prior to such termination date.

In exchange for the license, the gross value of the intangible asset capitalized was $2.3 million. License and supply agreement, net, on the consolidated balance sheet is $0.3 million and $0.4 million as of September 30, 2023 and December 31, 2022, respectively. Accumulated amortization is $2 million and $1.9 million as of September 30, 2023 and December 31, 2022, respectively. The intangible asset is being amortized as an expense over the life of the License and Supply Agreement. Amortization expense of approximately $33,000 was recognized in each of the three months ended September 30, 2023 and 2022 on the consolidated statement of operations and comprehensive loss.

As of September 2013, the Company has an understanding with Medica whereby the Company has agreed to pay interest to Medica at a 12% annual rate calculated on the principal amount of any outstanding invoices that are not paid pursuant to the original payment terms. There was no interest recognized for the nine months ended September 30, 2023 or September 30, 2022.

In addition, for the period beginning April 23, 2014 through December 31, 2025, the Company will pay Medica a royalty rate of 3% of net sales of the filtration products sold, subject to reduction as a result of a supply interruption pursuant to the terms of the License and Supply Agreement. Approximately $102,000 and $64,000 for the three months ended September 30, 2023 and 2022, respectively, was recognized as royalty expense and is included in cost of goods sold on the consolidated statement of operations and comprehensive loss. Approximately $292,000 and $198,000 for the nine months ended September 30, 2023 and 2022, respectively, was recognized as royalty expense and is included in cost of goods sold on the consolidated statement of operations and comprehensive loss. Approximately $102,000 and $71,000 of this royalty expense was included in accounts payable as of September 30, 2023 and December 31, 2022, respectively.

Note 9 – Secured Note Payable

On March 27, 2018, the Company entered into a Secured Promissory Note Agreement (the “Secured Note”) with Tech Capital for a principal amount of $1.2 million. As of September 30, 2023, the principal balance of the Secured Note was paid off.

The Secured Note had a maturity date of April 1, 2023. The unpaid principal balance accrued interest at a rate of 8% per annum. Principal and interest payments were due on the first day of each month commencing on May 1, 2018. The Secured Note was subject to terms and conditions of and was secured by security interests granted by the Company in favor of Tech Capital under the Loan and Security Agreement entered into on August 17, 2017 and subsequently amended on December 20, 2019 (the “Loan Agreement”). An event of default under such Loan Agreement was an event of default under the Secured Note and vice versa.

During the three months ended September 30, 2023, no payments were made under the Secured Note, as the Note was repaid in full at March 31, 2023. During the three months ended September 30, 2022, the Company made payments under the Secured Note of approximately $72,000. Included in the total payments made, approximately $4,000 was recognized as interest expense on the consolidated statement of operations and comprehensive loss for the three months ended September 30, 2022.

During the nine months ended September 30, 2023 and September 30, 2022, the Company made payments under the Secured Note of approximately $71,000 and $216,000, respectively. Included in the total payments made, approximately $1,000 and $15,000 was recognized as interest expense on the consolidated statements of operations and comprehensive loss for the nine months ended September 30, 2023 and September 30, 2022.

Note 10 – Leases

The Company has operating leases for corporate offices, an automobile and office equipment. The leases have remaining lease terms of 1 year to 5 years.

Lease cost, as presented below, includes costs associated with leases for which right-of-use (“ROU”) assets have been recognized as well as short-term leases.

The components of total lease costs were as follows:

		Three months ended September 30, 2023		Three months ended September 30, 2022
	(in thousands)
Operating lease cost		$	90	$	103
Finance lease cost:
Amortization of right-of-use assets			2		2
Interest on lease liabilities			-		1
Total finance lease cost			2		3
Variable lease cost			2		9
Total lease cost		$	94	$	115

	Nine months ended September 30, 2023		Nine months ended September 30, 2022
	(in thousands)
Operating lease cost	$	272	$	316
Finance lease cost:
Amortization of right-of-use assets		6		7
Interest on lease liabilities		2		4
Total finance lease cost		8		11
Variable lease cost		9		28
Total lease cost	$	289	$	355

Supplemental cash flow information related to leases was as follows:

	Nine months ended September 30, 2023		Nine months ended September 30, 2022
	(in thousands)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	272	$	316
Financing cash flows from finance leases	$	4	$	3

Supplemental balance sheet information related to leases was as follows:

	September 30, 2023			December 31, 2022
	(in thousands)
Operating lease right-of-use assets	$	744		$	972
Finance lease right-of-use assets	$	6		$	12

Current portion of operating lease liabilities	$	305		$	309
Operating lease liabilities, net of current portion		469			700
Total operating lease liabilities	$	774		$	1,009

Current portion of finance lease liabilities	$	6		$	8
Finance lease liabilities, net of current portion		-			4
Total finance lease liabilities	$	6		$	12

Weighted average remaining lease term
Operating leases		3.4 years			3.9 years
Finance leases		0.8 years			1.5 years

Weighted average discount rate
Operating leases		8.0	%		8.0	%
Finance leases		8.0	%		8.0	%

As of September 30, 2023, maturities of lease liabilities were as follows:

	Operating Leases			Finance Leases
	(in thousands)
2023 (excluding the nine months ended September 30, 2023)	$	53		$	2
2024		299			4
2025		163			-
2026		168			-
2027		158			-
Total future minimum lease payments		841			6
Less imputed interest		(67	)		-
Total	$	774		$	6

Note 11 – Stock Plans and Share-Based Payments

The fair value of stock options and restricted stock is recognized as stock-based compensation expense in the Company’s consolidated statement of operations and comprehensive loss. The Company calculates stock-based compensation expense in accordance with ASC 718. The fair value of stock-based awards is amortized over the vesting period of the award.

Stock Options

The Company granted stock options to purchase 6,000 and 453,065 shares of common stock, respectively, to employees during the three and nine months ended September 30, 2023. These stock options are being expensed over the respective vesting period, which is based on a service condition. The fair value of the stock options granted during the three and nine months ended September 30, 2023, was approximately $0.4 million.

The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model. The below assumptions for the risk-free interest rates, expected dividend yield, expected lives and expected stock price volatility were utilized for the stock options granted during the nine months ended September 30, 2023.

Assumptions for Option Grants
Stock Price Volatility	74.03	%
Risk-Free Interest Rate	3.44	%
Expected Life (in years)	6.21
Expected Dividend Yield	-	%

Stock-based compensation expense related to stock options was approximately $137,000 and $251,000 for the three months ended September 30, 2023 and 2022, respectively. For the three months ended September 30, 2023, approximately $134,000 and $3,000 are included in selling, general and administrative expenses and research and development expenses, respectively, on the accompanying consolidated statement of operations and comprehensive loss. For the three months ended September 30, 2022, approximately $227,000 and $24,000 are included in selling, general and administrative expenses and research and development expenses, respectively, on the accompanying consolidated statement of operations and comprehensive loss.

Stock-based compensation expense related to stock options was $486,000 and $724,000 for the nine months ended September 30, 2023 and 2022, respectively. For the nine months ended September 30, 2023, approximately $450,000 and $36,000 are included in selling, general and administrative expenses and research and development expenses, respectively, on the accompanying consolidated statement of operations and comprehensive loss. For the nine months ended September 30, 2022, approximately $669,000 and $55,000 are included in selling, general and administrative expenses and research and development expenses, respectively, on the accompanying consolidated statement of operations and comprehensive loss.

There was no tax benefit related to expense recognized in the three or nine months ended September 30, 2023 and 2022, as the Company is in a net operating loss position. As of September 30, 2023, there was approximately $819,000 of total unrecognized compensation expense related to unvested stock-based awards granted under the equity compensation plans, which will be amortized over the weighted average remaining requisite service period of 2.4 years.

Restricted Stock

Total stock-based compensation expense for restricted stock on the Company’s consolidated statement of operations was approximately $12,000 for the three months ended September 30, 2023 and a credit to expense of ($16,000) due to the forfeiture of 15,000 unvested restricted shares for the three months ended September 30, 2022. For the three months ended September 30, 2023, approximately $12,000 is included in selling, general and administrative expenses on the accompanying consolidated statement of operations and comprehensive loss. For the three months ended September 30, 2022, approximately ($16,000) is included in selling, general and administrative expenses on the accompanying consolidated statement of operations and comprehensive loss.

Total stock-based compensation expense for restricted stock was approximately $49,000 and $42,000 for the nine months ended September 30, 2023 and 2022, respectively. For the nine months ended September 30, 2023, approximately $49,000 is included in selling, general and administrative expenses on the accompanying consolidated statement of operations and comprehensive loss. During the nine months ended September 30, 2023, 23,781 shares of restricted stock were issued to employees and 133,722 shares of restricted stock were issued to board members related to services rendered during the year ended December 31, 2022. In addition, 30,000 shares of restricted stock were issued to contractors during the nine months ended September 30, 2023. All restricted shares issued during the nine months ended September 30, 2023, have a vesting period of six months. For the nine months ended September 30, 2022, approximately $42,000 is included in selling, general and administrative expenses on the accompanying consolidated statement of operations and comprehensive loss.

As of September 30, 2023, there was no unrecognized compensation expense related to unvested stock-based awards granted under the equity compensation plans.

SRP Equity Incentive Plan

SRP’s 2019 Equity Incentive Plan was approved on May 7, 2019 under which 150,000 shares of SRP’s common stock are reserved for the issuance of options and other awards. This plan is no longer operational, due to the wind down of SRP’s operations and its April 2023 dissolution.

Due to the Company’s deemed acquisition of the non-controlling interest in SRP during the nine months ended September 30, 2023, all remaining equity-based awards have been forfeited and no further expense will be incurred related to these awards. There were no SRP stock options or other equity awards granted during the nine months ended September 30, 2023. For the nine months ended September 30, 2023, a credit of approximately ($27,000) was recognized for expense related to the SRP equity-based awards. Stock-based compensation expense related to the SRP stock grants was approximately $19,000 and $37,000, for the three and nine months ended September 30, 2022. Stock-based compensation expense related to the SRP equity-based awards is included in selling, general and administrative expenses on the accompanying consolidated statement of operations and comprehensive loss. Stock-based compensation expense related to the SRP stock options is presented by the Company as noncontrolling interest on the consolidated balance sheet as of December 31, 2022.

Note 12 – Stockholders’ Equity

Noncontrolling Interest

Pursuant to the terms and conditions of a Series A Preferred Stock Purchase Agreement, dated September 9, 2018, among SRP and the purchasers identified therein (the “SRP Purchase Agreement”), SRP sold to such purchasers an aggregate of 600,000 shares of its Series A Preferred Stock (the “Series A Preferred”) at a price of $5.00 per share resulting in total gross proceeds of $3.0 million. On February 1, 2022, SRP and such purchasers amended the SRP Purchase Agreement to allow for the sale of an additional 100,003 shares of Series A Preferred, all of which were sold on February 4, 2022, for aggregate gross proceeds of $500,015 and otherwise on the same terms and conditions as set forth in the SRP Purchase Agreement. Approximately $188,000 of the proceeds from the February 2022 sales were recorded as an increase to the equity of the non-controlling interests. The Company purchased 62,500 shares of SRP’s Series A Preferred at such closing and, as a result, maintained its 62.5% stock ownership position in SRP. The other purchasers at the February 2022 closing included the Company’s Chief Executive Officer, who purchased 313 shares, and Lambda Investors LLC (“Lambda”), an affiliate of Wexford Capital, which together with its affiliates owns approximately 36% of the Company’s common stock, which purchased 25,938 shares of the Series A Preferred in February 2022. Such purchases were made on the same terms as all other purchasers. In addition to the funds provided by the SRP Purchase Agreement, the Company loaned to SRP to the principal amount of $1.3 million, $1.0 million of which was advanced during the year ended December 31, 2020.

As of December 31, 2022, the non-controlling interest in SRP held by holders of the Series A Preferred has been classified as equity on the accompanying consolidated interim balance sheet, as the non-controlling interest is redeemable only upon the occurrence of events that are within the control of the Company. As a result of the adoption of the plan of liquidation and dissolution by SRP’s stockholders and the subsequent filing of a certificate of dissolution of SRP with the State of Delaware, the redemption feature related to the Series A Preferred Stock effectively terminated. As such, the value of the Series A Preferred Stock previously presented in non-controlling interest was reclassified to additional paid in capital as the Company retained control of SRP.

In March 2023, the board of directors of SRP adopted, and the stockholders of SRP approved, a plan to wind down SRP’s operations and dissolve, and in April 2023, SRP filed a certificate of dissolution with the State of Delaware. In accordance with its plan of dissolution, after SRP satisfied its other outstanding liabilities, SRP assigned to the Company all of its remaining assets, including its intellectual property rights, in satisfaction of outstanding indebtedness owed to the Company in the approximate amount of $1.5 million. No other assets are available for distribution to any of SRP’s stockholders, including the Company, in respect of their shares of SRP capital stock, including the Series A Preferred. As a result of the dissolution described above, it was determined approximately $24,000 of inventory likely had no value, and was written off in the period ended March 31, 2023.

Warrants

During the three and nine months ended September 30, 2023, the Company had no outstanding warrants.

During the nine months ended September 30, 2022, warrants to purchase 60,374 shares of the Company’s common stock were exercised, resulting in proceeds of $0.2 million and the issuance of 60,374 shares of the Company’s common stock. Of the warrants exercised during the nine months ended September 30, 2022, warrants to purchase 14,815 shares of the Company’s common stock were exercised by members of management, resulting in proceeds of approximately $40,000. Warrants to purchase 63,102 shares of the Company’s common stock expired unexercised, during the nine months ended September 30, 2022.

Note 13 – Net Loss per Common Share

Basic loss per common share is calculated by dividing net loss available to common shareholders by the number of weighted average common shares issued and outstanding. Diluted loss per common share is calculated by dividing net loss available to common shareholders by the weighted average number of common shares issued and outstanding for the period, plus amounts representing the dilutive effect from the exercise of stock options and warrants and unvested restricted stock, as applicable. The Company calculates dilutive potential common shares using the treasury stock method, which assumes the Company will use the proceeds from the exercise of stock options and warrants to repurchase shares of common stock to hold in its treasury stock reserves.

The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as they would be antidilutive:

	September 30,
	2023		2022
Shares underlying options outstanding		1,767,443		1,492,247

Note 14 – Commitments and Contingencies

Purchase Commitments

In exchange for the rights granted under the License and Supply Agreement with Medica (see Note 8 – License and Supply Agreement, net), the Company agreed to make certain minimum annual aggregate purchases from Medica over the term of the License and Supply Agreement. For the year ended December 31, 2023, the Company has agreed to make minimum annual aggregate purchases from Medica of €3.8 million (approximately $4.1 million). As of September 30, 2023, the Company’s aggregate purchase commitments totaled €4.5 million (approximately $4.8 million).

Contractual Obligations

See Note 10 – Leases for a discussion of the Company’s contractual obligations.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion should be read in conjunction with our consolidated financial statements and notes thereto included in Item 1 of Part I of this Quarterly Report on Form 10-Q. This discussion includes forward-looking statements about our business, financial condition and results of operations including discussions about management’s expectations for our business. These statements represent projections, beliefs and expectations based on current circumstances and conditions and in light of recent events and trends, and these statements should not be construed either as assurances of performances or as promises of a given course of action. Instead, various known and unknown factors are likely to cause our actual performance and management’s actions to vary, and the results of these variances may be both material and adverse.

Business Overview

We are a commercial-stage company that develops and sells high performance water solutions to the medical and commercial markets.

Our medical water filters, mostly classified as ultrafilters, are used primarily by hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, and in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate. Because our ultrafilters capture contaminants as small as 0.005 microns in size, they minimize exposure to a wide variety of bacteria, viruses, fungi, parasites, and endotoxins.

Our commercial water filters improve the taste and odor of water and reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. Our products are marketed primarily to the food service, hospitality, convenience store, and health care markets, and also sold into medical institutions to supplement.

We previously held a majority stake in Specialty Renal Products, Inc. (“SRP”), a development-stage medical device company that was focused primarily on developing hemodiafiltration (“HDF”) technology. On May 13, 2022, the FDA gave 510(k) clearance to SRP’s second-generation model of the OLpūrH2H Hemodiafiltration System, which enables nephrologists to provide HDF treatment to patients with end stage renal disease. In January 2023, SRP management began exploring strategic partnerships to support a commercial launch of the HDF product but was unsuccessful in identifying a partner. By late February 2023, SRP had nearly exhausted its capital resources. Due to its limited capital and lack of prospects for securing a strategic partnership or additional financing, the board of directors of SRP adopted a plan on March 6, 2023 to wind down SRP operations, liquidate its remaining assets and dissolve the company. That plan was approved by SRP’s stockholders on March 9, 2023, and on April 11, 2023, SRP filed a certificate of dissolution with the State of Delaware. SRP’s cash resources were sufficient to satisfy all of its outstanding liabilities other than its obligations to us under a loan with an outstanding balance of approximately $1.5 million. Accordingly, SRP assigned to Nephros all of its remaining assets, including its intellectual property rights in the HDF2 device, in satisfaction of its outstanding loan balance. Although we have no current plans to do so, we may re-evaluate opportunities for HDF in the future.

Our Products

Water Filtration Products

We develop and sell water filtration products used in both medical and commercial applications. Our water filtration products employ multiple filtration technologies, as described below.

In medical markets, our primary filtration mechanism is to pass liquids through the pores of polysulfone hollow fiber. Our filters’ pores are significantly smaller than those of competing products, resulting in highly effective elimination of waterborne pathogens, including legionella bacteria (the cause of Legionnaires disease) and viruses, which are not eliminated by most other microbiological filters on the market. Additionally, the fiber structure and pore density in our hollow fiber enables significantly higher flow rates than in other polysulfone hollow fiber.

Our primary sales strategy in medical markets is to sell through value-added resellers (“VARs”). Leveraging VARs has enabled us to expand rapidly our access to target customers with limited sales staff expansion. In addition, while we are currently focused on medical markets, the VARs that support these customers also support a wide variety of commercial and industrial customers. We believe that our VAR relationships have and will continue to facilitate growth in filter sales outside of the medical industry.

In commercial markets, we develop and sell our filters, for which carbon-based absorption is the primary filtration mechanism. These products allow us to improve water’s odor and taste, to reduce scale and heavy metals, and to reduce other water contaminants for customers who are primarily in the food service, convenience store, and hospitality industries. These commercial products are also sold into medical markets, as supplemental filtration to our medical filters.

In commercial markets, our model combines both direct and indirect sales. Our sales staff have sold products directly to a number of convenience stores, hotels, casinos, and restaurants. We are also pursuing large corporate contracts through partnerships.

Target Markets

Our ultrafiltration products currently target the following markets:

	●	Hospitals and Other Healthcare Facilities: Filtration of water for washing and drinking as an aid in infection control. The filters produce water that is suitable for wound cleansing, cleaning of equipment used in medical procedures, and washing of surgeons’ hands.
	●	Dialysis Centers and Home/Portable Dialysis Machines: Filtration of water or bicarbonate concentrate used in hemodialysis.
	●	Commercial Facilities: Filtration and purification of water for consumption, including for use in ice machines and soft drink dispensers.
	●	Military and Outdoor Recreation: Individual water purification devices used by soldiers and backpackers to produce drinking water in the field, as well as filters customized to remote water processing systems.

Hospitals and Other Healthcare Facilities. Nephros filters are a leading tool used to provide proactive protection to patients in high-risk areas (e.g., ice machines, surgical rooms, NICUs) and reactive protection to patients in broader areas during periods of water pathogen outbreaks. Our products are used in hundreds of medical facilities to aid in infection control, both proactively and reactively.

As of 2022, according to the American Hospital Association, there are approximately 6,100 hospitals in the U.S., with approximately 921,000 beds. Over 33 million patients were admitted to these hospitals. The U.S. Centers for Disease Control and Prevention (“CDC”) estimates that healthcare associated infections (“HAI”) occur in approximately 1 out of every 31 hospital patients, which calculates to over one million patients in 2022. HAIs affect patients in hospitals or other healthcare facilities and are not present or incubating at the time of admission. They also include infections acquired by patients in the hospital or facility, but appearing after discharge, and occupational infections among staff. Many HAIs are caused by waterborne bacteria and viruses that can thrive in aging or complex plumbing systems often found in healthcare facilities.

In January 2022, the Center for Clinical Standards and Quality at the Centers for Medicare and Medicaid Services (“CMS”) expanded its requirements – originally implemented in 2017 – for facilities to develop policies and procedures that inhibit the growth and spread of legionella and other opportunistic pathogens in building water systems. In this 2022 update, CMS requires teams to be assigned to the development of formal water management plans (“WMPs”), as well as detailed documentation regarding the development of the WMPs and their execution. CMS surveyors regularly review policies, procedures, and reports documenting water management implementation results to verify that facilities are compliant with these requirements. We believe that these CMS regulations may have a positive impact on the sale of our HAI-inhibiting ultrafilters.

We currently have FDA 510(k) clearance on the following portfolio of medical device products for use in the hospital setting to aid in infection control:

●

The DSU-H and SSU-H are in-line, 0.005-micron ultrafilters that provide dual- and single-stage protection, respectively, from waterborne pathogens. They are primarily used to filter potable water feeding ice machines, sinks, and medical equipment, such as endoscope washers and surgical room humidifiers. The DSU-H has an up to 6-month product life in a typical hospital setting, while the SSU-H has an up to 3-month product life.

●	The S100 is a point-of-use, 0.01-micron microfilter that provides protection from waterborne pathogens. The S100 is primarily used to filter potable water feeding sinks and showers. The S100 has an up to 3-month product life when used in a hospital setting.

●	The HydraGuard^TM and HydraGuard^TM - Flush are 0.005-micron cartridge ultrafilters that provide single-stage protection from waterborne pathogens. The HydraGuard ultrafilters are primarily used to filter potable water feeding ice machines and medical equipment, such as endoscope washers and surgical room humidifiers. The HydraGuard has an up to 6-month product life and the HydraGuard - Flush has an up to 12-month product life when used in a hospital setting.

Our complete hospital infection control product line, including in-line, and point-of-use can be viewed on our website at https://www.nephros.com/infection-control/. We are not including the information on our website as a part of, nor incorporating it by reference into, this Quarterly Report on Form 10-Q.

Dialysis Centers - Water/Bicarbonate. In the dialysis water market, Nephros ultrafiltration products are among the highest performing products on the market. The DSU-D, SSU-D and the SSUmini have become the standard endotoxin filter in many portable reverse osmosis systems. The EndoPur^®, our large-format ultrafilter targeted at dialysis clinic water systems, provides the smallest pore size available.

To perform hemodialysis, all dialysis clinics have dedicated water purification systems to produce water and bicarbonate concentrate, two essential ingredients for making dialysate, the liquid that removes waste material from the blood. According to the American Journal of Kidney Diseases, there are approximately 6,500 dialysis clinics in the United States servicing approximately 468,000 patients annually. We estimate that there are over 100,000 hemodialysis machines in operation in the United States.

Medicare is the main payer for dialysis treatment in the United States. To be eligible for Medicare reimbursement, dialysis centers must meet the minimum standards for water and bicarbonate concentrate quality set by the Association for the Advancement of Medical Instrumentation (“AAMI”), the American National Standards Institute (“ANSI”) and the International Standards Organization (“ISO”). We anticipate that the stricter standards approved by these organizations in 2009 will be adopted by Medicare in the future.

We currently have FDA 510(k) clearance on the following portfolio of medical device products for use in the dialysis setting to aid in bacteria, virus, and endotoxin retention:

	●	The DSU-D, SSU-D and SSUmini are in-line, 0.005-micron ultrafilters that provide protection from bacteria, viruses, and endotoxins. All of these products have an up to 12-month product life in the dialysis setting and are used to filter water following treatment with a reverse osmosis (“RO”) system, and to filter bicarbonate concentrate. These ultrafilters are primarily used in the water lines and bicarbonate concentrate lines leading into dialysis machines, and as a polish filter for portable RO machines.

	●	The EndoPur is a 0.005-micron cartridge ultrafilter that provides single-stage protection from bacteria, viruses, and endotoxins. The EndoPur has an up to 12-month product life in the dialysis setting and is used to filter water following treatment with an RO system. More specifically, the EndoPur is used primarily to filter water in large RO systems designed to provide ultrapure water to an entire dialysis clinic. The EndoPur is a cartridge-based, “plug and play” market entry that requires no plumbing at installation or replacement. The EndoPur is available in 10”, 20”, and 30” configuration.

Commercial and Industrial Facilities. Our commercial NanoGuard^® product line accomplishes ultrafiltration via small pore size (0.005 micron) technology, filtering bacteria and viruses from water. In addition, our commercial filtration offerings include technologies that are primarily focused on improving odor and taste and on reducing scale from filtered water. Our commercial market focus includes the hospitality and food and beverage markets, in which we partner with Donastar Enterprises LLC as our master distributor. We also sell commercial filters into medical and non-medical facilities through our other distribution partners.

Over time, we believe that the same water safety management programs currently underway at medical facilities may migrate to commercial markets. As the epidemiology of waterborne pathogens expands, links to contamination sources will become more efficient and the data more readily available. In cases where those sources are linked to restaurants, hotels, office buildings and residential complexes, the corporate owners of those facilities will likely face increasing liability exposure. We expect that building owners will come to understand ASHRAE-188, which outlines risk factors for buildings and their occupants, and provides water safety management guidelines. We believe, in time, most commercial buildings will need to follow the basic requirements of ASHRAE-188: create a water management plan, perform routine testing, and establish a plan to treat the building in the event of a positive test.

As demand for water testing and microbiological filtration grows, we will be ready to deploy our expertise and solutions based on years of experience servicing the medical market. We believe that we have an opportunity to offer unique expertise and products to the commercial market, and that our future revenue from the commercial market could even surpass our infection control revenue.

We currently market the following portfolio of proprietary products for use in the commercial, industrial, and food service settings:

	●	The NanoGuard set of products are in-line, 0.005-micron ultrafilter that provides dual-stage retention of any organic or inorganic particle larger than 15,000 Daltons. NanoGuard products are designed to fit a variety of existing plumbing configurations, including 10” and 20” standard housings, and Nephros and Everpure® manifolds. Included in the NanoGuard product line are both conventional and flushable filters.

	●	The Nephros line of commercial filters provide a variety of technology solutions that improve water quality in food service, convenience store, hospitality, and industrial applications. Nephros filters improve water taste and odor, and reduce sediment, dirt, rust particles and other solids, chlorine and heavy minerals, lime scale build-up, and both particulate lead and soluble lead.

Nephros commercial products combine effectively with NanoGuard ultrafiltration technologies to offer full-featured solutions to the commercial water market, including to existing users of Everpure filter manifolds.

Pathogen Detection Systems (“PDS”)

In 2019, we expanded our portfolio of water solutions with the introduction of pathogen detection system (“PDS”) products and services, including our PluraPath pathogen detection system, which we developed to provide real-time data regarding the existence of a broad array of waterborne pathogens to the infection control teams responsible for executing a building or other facility’s water management plans. In the third quarter of 2021, we acquired the business of GenArraytion, Inc. (“GenArraytion”), including GenArraytion’s many proprietary assays, multiplexing technology, and selection methods for detecting waterborne pathogens and other microorganisms using Polymerase Chain Reaction technology. GenArraytion’s assets were integrated into our PDS segment. In November 2022, we sold substantially all of our assets used in our PDS business to BWSI, LLC pursuant to the terms of an Agreement for Purchase and Sale of Assets with BWSI (the “PDS Purchase Agreement”). Under the terms of the PDS Purchase Agreement, BWSI made a nominal cash payment at the closing of the transaction and assumed certain continuing liabilities of the PDS business. Additionally, for a period of seven years commencing January 1, 2023, and ending December 31, 2029, BWSI, after achieving certain minimum revenue levels from the sale and licensing of products developed by the PDS Business, will pay us an annual royalty equal to a specified percentage of gross margin earned by BWSI from additional such revenues.

Critical Accounting Policies

For the nine-month period ended September 30, 2023, there were no significant changes to our critical accounting policies as identified in our Annual Report on Form 10-K for the year ended December 31, 2022.

Recent Accounting Pronouncements

We are subject to recently issued accounting standards, accounting guidance and disclosure requirements. For a description of these new accounting standards, see Note 2, “Basis of Presentation and Liquidity,” of the Notes to our Unaudited Consolidated Interim Financial Statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.

Results of Operations

Fluctuations in Operating Results

Our results of operations have fluctuated significantly from period to period in the past, including recently, and are likely to continue to do so in the future. We anticipate that our annual results of operations will be impacted for the foreseeable future by several factors, including revenue growth rates, expense management, and maintaining positive operating cash flow. Due to these fluctuations, we believe that the period-to-period comparisons of our operating results are not a good indication of our future performance.

Three Months Ended September 30, 2023 Compared to the Three Months Ended September 30, 2022

The following table sets forth our summarized, consolidated results of operations for the three months ended September 30, 2023 and 2022 (in thousands, except percentages):

							$			%
							Increase			Increase
	2023			2022			(Decrease)			(Decrease)
Total net revenues	$	3,742		$	2,409		$	1,333			55	%
Cost of goods sold		1,548			1,647			(99	)		(6	)%
Gross margin		2,194			762			1,432			188	%
Gross margin %		59	%		32	%		-			84	%
Selling, general and administrative expense		2,137			1,743			394			23	%
Research and development expense		205			252			(47	)		(19	)%
Depreciation and amortization expense		55			48			7			15	%
Operating loss from continuing operations		(203	)		(1,281	)		1,078			(84	)%
Interest expense		-			(4	)		4			(100	)%
Interest income		11			4			7			175	%
Other income (expense), net		10			31			(21	)		(68	)%
Net loss from continuing operations		(182	)		(1,250	)		1,068			(85	)%
Net loss from discontinued operations		-			(1,904	)		1,904			(100	)%
Net loss		(182	)		(3,154	)		2,972			(94	)%
Less: Undeclared deemed dividend attributable to noncontrolling interest		-			(77	)		77			(100	)%
Net loss attributable to Nephros, Inc.	$	(182	)	$	(3,231	)	$	3,049			(94	)%

Revenue

The increase in net revenues of $1.3 million, or 55%, was driven by investments in our executive and sales organizations, as well as partnering with a master distributor for much of our commercial business. These investments generated approximately 42% growth in our core, programmatic business.

Gross Profit Margin

Gross margin was approximately 59% for the three months ended September 30, 2023, compared to approximately 32% for the three months ended September 30, 2022. The increase of approximately 27 percentage points reflects a return to target gross margins of 55-60%. Lower gross margins in 2022 were primarily driven by large inventory write-downs in the third quarter of 2022. In addition, gross margins were favorably impacted by reductions in shipping expenses, and improved inventory management.

Selling, General and Administrative Expenses

Selling, general, and administrative expenses increased $0.4 million, or 23%, primarily due primarily to increased commissions of $0.1 million, investment in our general and administrative headcount of $0.2 million, increased bonus accruals of $0.1 million, and investment in our facility consolidation effort of $0.1 million. These were offset by $0.1 million in lower professional services, stock compensation, and rent expense.

Research and Development Expenses

Research and development expenses decreased approximately $47,000 due to the wind down of SRP and slightly decreased investment in water filter research and development.

Depreciation and Amortization Expense

Depreciation and amortization expenses were approximately $55,000 and $48,000, respectively, for the three months ended September 30, 2023, and 2022.

Interest Expense

There was no interest expense for the three months ended September 30, 2023. Interest expense was approximately $4,000 for the three months ended September 30, 2022, comprised primarily of interest on our secured note payable.

Interest Income

Interest income was approximately $11,000 for the three months ended September 30, 2023 compared to approximately $4,000 for the three months ended September 30, 2022.

Other Income (Expense), net

Other income of approximately $10,000 for the three months ended September 30, 2023 is primarily a result of gains on foreign currency transactions. Other income of approximately $31,000 for the three months ended September 30, 2022 is primarily related foreign currency exchange gains.

Nine Months Ended September 30, 2023 Compared to the Nine Months Ended September 30, 2022

The following table sets forth our summarized, consolidated results of operations for the nine months ended September 30, 2023 and 2022 (in thousands, except percentages):

							$			%
							Increase			Increase
	2023			2022			(Decrease)			(Decrease)
Total net revenues	$	10,984		$	7,417		$	3,567			48	%
Cost of goods sold		4,600			4,195			405			10	%
Gross margin		6,384			3,222			3,162			98	%
Gross margin %		58	%		43	%		-			35	%
Selling, general and administrative expense		6,500			5,806			694			12	%
Research and development expense		665			896			(231	)		(26	)%
Depreciation and amortization expense		163			162			1			1	%
Operating loss from continuing operations		(944	)		(3,642	)		2,698			(74	)%
Interest expense		(1	)		(17	)		16			(94	)%
Interest income		36			7			29			414	%
Other income (expense), net		(12	)		94			(106	)		(113	)%
Net loss from continuing operations		(921	)		(3,558	)		2,637			(74	)%
Ner loss from discontinued operations		-			(2,700	)		2,700			(100	)%
Net loss		(921	)		(6,258	)		5,337			(85	)%
Less: Undeclared deemed dividend attributable to noncontrolling interest		-			(206	)		206			(100	)%
Net loss attributable to Nephros, Inc.	$	(921	)	$	(6,464	)	$	5,543			(86	)%

Revenue

The increase in net revenues of $3.6 million, or 48%, was driven by two factors. First, we invested in our sales organization, increasing medical sales headcount significantly and partnering with a master distributor for much of our commercial business. These investments generated approximately 34% growth in our core, programmatic business. Second, we received an unusually large emergency response order, which generated approximately $600,000 of additional revenue in the first quarter of 2023.

Gross Profit Margin

Gross margin was approximately 58% for the nine months ended September 30, 2023, compared to approximately 43% for the nine months ended September 30, 2022. The increase of approximately 15 percentage points reflects a return to target gross margins of 55-60%. Lower gross margins in 2022 were primarily driven by large inventory write-downs and higher shipping expenses. In addition, gross margins in 2023 were favorably impacted by price increases implemented in the second half of 2022.

Selling, General and Administrative Expenses

Selling, general, and administrative expenses increased $0.7 million, or 12% primarily due primarily to increased commissions of $0.4 million, investment in our general and administrative headcount of $0.2 million, and increased bonus accruals of $0.2 million. These were offset by $0.1 million in lower professional services and stock compensation.

Research and Development Expenses

Research and development expenses decreased $231,000 primarily due to due to the wind down of SRP and slightly decreased investment in water filter research and development.

Depreciation and Amortization Expense

Depreciation and amortization expenses were approximately $163,000 and $162,000, respectively, for the nine months ended September 30, 2023 and 2022.

Interest Expense

Interest expense was approximately $1,000 for the nine months ended September 30, 2023 compared to $17,000 for the nine months ended September 30, 2022. This reduction is primarily related to a lower principal balance of the company’s secured note payable.

Interest Income

Interest income was approximately $36,000 for the nine months ended September 30, 2023 compared to approximately $7,000 for the nine months ended September 30, 2022.

Other Income (Expense), net

Other expense was approximately $12,000 for the nine months ended September 30, 2023 and is primarily a result of losses on foreign currency transactions. Other income was approximately $94,000 for the nine months ended September 30, 2022 and is primarily related to the release of the cumulative translation adjustment from accumulated other comprehensive income (loss) on the liquidation of a foreign entity and of gains on foreign currency transactions related to the closure in the second quarter of 2022, of Nephros International, a wholly owned subsidiary of Nephros, Inc.

Liquidity and Capital Resources

The following table summarizes our liquidity and capital resources as of September 30, 2023 and December 31, 2022 and is intended to supplement the more detailed discussion that follows. The amounts stated are expressed in thousands.

	September 30,		December 31,
Liquidity and Capital Resources	2023		2022
Cash and cash equivalents	$	4,622	$	3,634
Other current assets		3,884		4,627
Working capital		6,678		6,849
Stockholders’ equity		8,622		8,881

At September 30, 2023, we had an accumulated deficit of $143.8 million and we may incur additional operating losses from operations until such time, if ever, that we are able to increase revenue to achieve profitability.

Based on cash that is available for our operations and projections of our future operations, as well as our significantly reduced cash burn rates over the past nine months, we believe that our cash balances will be sufficient to fund our current operating plan through at least the next 12 months from the date of issuance of the consolidated financial statements in this Quarterly Report on Form 10-Q. Additionally, our operating plans are designed to help control operating costs, to increase revenue, and to raise additional capital until such time as we generate sufficient cash flows to fund operations. If there were a decrease in the demand for our products due to either economic or competitive conditions, or if we are otherwise unable to achieve our plan or achieve our anticipated operating results, there could be a significant reduction in liquidity due to our possible inability to cut costs sufficiently. In such event, the Company may need to take further actions to reduce its discretionary expenditures, including further reducing headcount, reducing spending on R&D projects, and reducing other variable costs.

Our future liquidity sources and requirements will depend primarily on revenue growth rates and our ability to produce, market and sell our products effectively and efficiently. We expect to put our current capital resources toward the development, marketing, and sales of our water filtration products and working capital purposes.

Net cash provided by operating activities was $1.1 million for the nine months ended September 30, 2023, compared to net cash used in operating activities of approximately $3.0 million for the nine months ended September 30, 2022, an increase of $4.1 million due primarily to a decrease of $5.3 million in net loss as a result of increased revenue for the nine months ended September 30, 2023 compared to 2022, increased gross margins, and decreased research and development costs. In addition, a reduction in inventory levels provided approximately $0.8 million, and increases in accounts payable and accrued expenses provided an additional $0.5 million in cash, all of which was partially offset by an increase in accounts receivable, which used approximately $0.2 million in cash. These factors were a result of the large increase in sales for the period. While cash flows may fluctuate in the near term, we believe that future cash flows will continue to trend positive over the coming quarters.

We had no investing activities for the nine months ended September 30, 2023. Net cash used in investing activities was approximately $137,000 in the nine months ended September 30, 2022, due to purchases of property and equipment.

Net cash used in financing activities was approximately $0.1 million for the nine months ended September 30, 2023, primarily due to final principal payments on since-retired debt. Net cash provided by financing activities for the nine months ended September 30, 2022 was approximately $0.1 million, primarily from proceeds from the exercise of warrants of $0.2 million and from the sale to Nephros of SRP preferred shares of $0.2 million, offset partially by payments of $0.2 million on our secured note, principal payments of approximately $3,000 on our finance lease obligation and principal payments of approximately $2,000 on our equipment financing debt.

Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements as of September 30, 2023.

Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain statements in this Quarterly Report on Form 10-Q constitute “forward-looking statements”. Such statements include statements regarding the efficacy and intended use of our technologies under development, the timelines and strategy for bringing such products to market, the timeline for regulatory review and approval of our products, the availability of funding sources for continued development of such products, and other statements that are not historical facts, including statements which may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guaranties of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond our control. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include, but are not limited to, the risks that:

	●	we may be unable to achieve or sustain revenue growth;
	●	product-related deaths or serious injuries or product malfunctions could trigger recalls, class action lawsuits and other events that could cause us to incur expenses and may also limit our ability to generate revenues from such products;
	●	we face potential liability associated with the production, marketing and sale of our products, and the expense of defending against claims of product liability could materially deplete our assets and generate negative publicity, which could impair our reputation;
	●	to the extent our products or marketing materials are found to violate any provisions of the U.S. Food, Drug and Cosmetic Act (the “FDC Act”) or any other statutes or regulations, we could be subject to enforcement actions by the U.S. Food and Drug Administration (the “FDA”) or other governmental agencies;
	●	we may not be able to obtain funding when needed or on terms favorable to us in order to continue operation;
	●	we may not have sufficient capital to successfully implement our business plan;
	●	we may not be able to effectively market our products;
	●	we may not be able to sell our water filtration products at competitive prices or profitably;
	●	we may encounter problems with our suppliers, manufacturers, and distributors;
	●	we may encounter unanticipated internal control deficiencies or weaknesses or ineffective disclosure controls and procedures;
	●	we may not be able to obtain appropriate or necessary regulatory approvals to achieve our business plan;
	●	we may not be able to secure or enforce adequate legal protection, including patent protection, for our products; and
	●	we may not be able to achieve sales growth in key geographic markets.

More detailed information about us and the risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this Quarterly Report on Form 10-Q, is set forth in our filings with the U.S. Securities and Exchange Commission (the “SEC”), including our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and our other reports filed with the SEC. We urge investors and security holders to read those documents free of charge at the SEC’s web site at www.sec.gov. We do not undertake to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise, except as required by law.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Not required for smaller reporting companies.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

We maintain a system of disclosure controls and procedures, as defined in Rule 13a-15(e) or Rule 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which is designed to provide reasonable assurance that information required to be disclosed in our reports filed pursuant to the Exchange Act is accumulated and communicated to management in a timely manner. Management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives. Because there are inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud have been or will be detected.

At the end of the period covered by this Quarterly Report on Form 10-Q, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, regarding the effectiveness of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-15(b). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1A. Risk Factors

As a smaller reporting company, we are not required to provide disclosure pursuant to this item. However, in addition to other information set forth in this Quarterly Report on Form 10-Q, including the important information in the section entitled “Forward Looking Statements,” you should carefully consider the “Risk Factors” in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2022 for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in this Quarterly Report on Form 10-Q. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial might materially adversely affect our actual business, financial condition and/or operating results.

Item 6. Exhibits

EXHIBIT INDEX

Exhibit No.		Description of Exhibit

10.1		Employment Agreement dated August 9, 2023, between Nephros, Inc. and Andrew Astor *†

31.1		Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. *

31.2		Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. *

32.1		Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. **

32.2		Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. **

101		Interactive Data File. *

101.INS		Inline XBRL Instance Document*

101.SCH		Inline XBRL Taxonomy Extension Schema Document

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

*		Filed herewith
**		Furnished herewith
†		Management contract or compensatory plan arrangement

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	NEPHROS, INC.

Date: November 8, 2023	By:	/s/ Robert Banks
	Name:	Robert Banks
	Title:	President, Chief Executive Officer (Principal Executive Officer)

Date: November 8, 2023	By:	/s/ Judy Krandel
	Name:	Judy Krandel
	Title:	Chief Financial Officer (Principal Financial and Accounting Officer)

Exhibit 10.1

August 9, 2023

Andrew Astor

[Address]

Dear Andy,

Reference is made to that certain Employment Agreement between you and Nephros, Inc. (the “Company”) dated August 23, 2020 (the “Employment Agreement”). This letter agreement is intended to serve as an amendment to the Employment Agreement by setting forth modified terms of your employment with the Company following your retirement and resignation as the Company’s President and CEO and from the Company’s board of directors, which became effective as of May 11, 2023. Accordingly, you and the Company agree as follows:

1. Change in Status. Following your retirement as President and CEO, you have agreed to remain employed as the Company’s interim Chief Financial Officer (“CFO”). As CFO, you will be responsible for, among other matters, leading the financial and risk management operations of the Company, including tracking financial strategies and supporting the ongoing development and monitoring of control systems designed to preserve company assets and to report accurate financial results. Additionally, you will remain as the Company’s principal financial officer and principal accounting officer. Further, you will assist the Company’s President and CEO in his transition to such positions and provide such other assistance and services as he and/or the board may reasonably request. Your continued employment as CFO will be on an “at-will” basis, meaning that your employment may be terminated by either you or the Company at any time.

2. Salary. Your annualized base salary will initially be the same as your prior salary as President and CEO. However, you and the Company understand that as your progress further in your transition as CFO, you and the Company expect that the amount of time required to fulfill your CFO obligations will decline from full-time. Accordingly, you and the Company agree on a monthly basis to re-evaluate the amount of time required to fulfill your duties as CFO and your annualized base salary will be adjusted pro rata to reflect such reduced time commitment.

3. 2023 Cash Bonus. Even if you do not remain employed by the Company as of December 31, 2023, you will be eligible to receive your 2023 cash bonus, based upon achievement of the corporate goals and milestones previously approved by the Company’s Board of Directors (the “Board”), as determined in the Board’s discretion, which amount will be adjusted pro rata based on the period of your employment with the Company and the percentage of time dedicated to such employment during 2023; provided, that your eligibility for such bonus award shall be subject to your continued assistance in assisting in the transition to the Company’s new President and CEO and its to-be-hired CFO.

4. Option Awards. In consideration of your assistance with the transition to the Company’s new management team, the Company agrees to the following with respect to the currently outstanding stock option awards that have been granted to you pursuant to the Company’s 2015 Equity Incentive Plan (the “2015 Plan” and such awards, the “Stock Options”):

Subject to your continued employment or other services relationship with the Company, each Stock Option that has not yet vested in full will continue to vest in accordance with the vesting schedule described in the award agreement evidencing such Stock Option.

Notwithstanding the terms of each agreement evidencing a Stock Option (each, a “Stock Option Agreement”), after your employment or service relationship with the Company ceases, your right to purchase one-half of the shares subject to such Stock Options that are vested as of the date of such termination of services shall continue to be exercisable until December 31, 2026, and the remaining one-half of vested shares shall continue to be exercisable in accordance with the terms of the applicable Stock Option Agreement; provided, however, that in the event you voluntarily terminate your employment or service relationship with the Company without the consent of the Company, then the post-termination exercise periods described in each Stock Option Agreement shall not be extended beyond the terms set forth therein.

This Paragraph 4 is intended to operate as an amendment to each of the applicable Stock Option Agreements.

5. Prior Employment Agreement. This shall confirm that Sections 1, 2.1, 2.4, 3.1 through 3.4 and 4 of the Employment Agreement are hereby deleted and without further force or effect, but all other provisions of the Employment Agreement shall continue in accordance with their terms, as modified by this letter agreement.

Kindly acknowledge your agreement with the foregoing by countersigning this letter in the space provided below.

	Sincerely,

	Nephros, Inc.

	/s/ Robert Banks
	Robert Banks
	President and Chief Executive Officer

Acknowledged and agreed:

/s/ Andrew Astor
Andrew Astor

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

UNDER SECTION 302 OF THE SARBANES-OXLEY ACT

I, Robert Banks, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Nephros, Inc.

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 8, 2023	By:	/s/ Robert Banks
	Name:	Robert Banks
	Title:	President, Chief Executive Officer (Principal Executive Officer)

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

UNDER SECTION 302 OF THE SARBANES-OXLEY ACT

I, Andrew Astor, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Nephros, Inc.

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 8, 2023	By:	/s/ Judy Krandel
	Name:	Judy Krandel
	Title:	Chief Financial Officer (Principal Financial and Accounting Officer)

Exhibit 32.1

Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of Nephros, Inc. (the “Company”) for the period ended September 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Robert Banks, President, Chief Executive Officer of the Company, certifies that:

1.	the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By:	/s/ Robert Banks
Name:	Robert Banks
Title:	President, Chief Executive Officer (Principal Executive Officer)

Dated: November 8, 2023

Exhibit 32.2

Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of Nephros, Inc. (the “Company”) for the period ended September 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Andrew Astor, Chief Financial Officer of the Company, certifies that:

1.	the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By:	/s/ Judy Krandel
Name:	Judy Krandel
Title:	Chief Financial Officer (Principal Financial and Accounting Officer)

Date:	November 8, 2023

Cover - shares	9 Months Ended
Cover - shares	Sep. 30, 2023	Nov. 06, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2023
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-32288
Entity Registrant Name	NEPHROS, INC.
Entity Central Index Key	0001196298
Entity Tax Identification Number	13-3971809
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	380 Lackawanna Place
Entity Address, City or Town	South Orange
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07079
City Area Code	(201)
Local Phone Number	343-5202
Title of 12(b) Security	Common stock, par value $0.001 per share
Trading Symbol	NEPH
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		10,484,932

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 4,622	$ 3,634
Accounts receivable, net	1,443	1,286
Inventory	2,268	3,153
Prepaid expenses and other current assets	173	188
Total current assets	8,506	8,261
Property and equipment, net	88	116
Lease right-of-use assets	750	984
Intangible assets, net	392	423
Goodwill	759	759
License and supply agreement, net	301	402
Other assets	123	54
TOTAL ASSETS	10,919	10,999
Current liabilities:
Current portion of secured note payable		71
Accounts payable	805	740
Accrued expenses	712	285
Current portion of lease liabilities	311	316
Total current liabilities	1,828	1,412
Equipment financing, net of current portion		1
Lease liabilities, net of current portion	469	705
TOTAL LIABILITIES	2,297	2,118
COMMITMENTS AND CONTINGENCIES (Note 14)
STOCKHOLDERS’ EQUITY
Preferred stock, $.001 par value; 5,000,000 shares authorized at September 30, 2023 and December 31, 2022; no shares issued and outstanding at September 30, 2023 and December 31, 2022.
Common stock, $.001 par value; 40,000,000 shares authorized at September 30, 2023 and December 31, 2022; 10,484,932 and 10,297,429 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively.	10	10
Additional paid-in capital	152,364	148,413
Accumulated deficit	(143,752)	(142,831)
Subtotal	8,622	5,592
Noncontrolling interest		3,289
TOTAL STOCKHOLDERS’ EQUITY	8,622	8,881
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 10,919	$ 10,999

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	40,000,000	40,000,000
Common stock, shares issued	10,484,932	10,297,429
Common stock, shares outstanding	10,484,932	10,297,429

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Net revenue:
Total net revenues	$ 3,742	$ 2,409	$ 10,984	$ 7,417
Cost of goods sold	1,548	1,647	4,600	4,195
Gross margin	2,194	762	6,384	3,222
Operating expenses:
Selling, general and administrative	2,137	1,743	6,500	5,806
Research and development	205	252	665	896
Depreciation and amortization	55	48	163	162
Total operating expenses	2,397	2,043	7,328	6,864
Operating loss from continuing operations	(203)	(1,281)	(944)	(3,642)
Other (expense) income:
Interest expense		(4)	(1)	(17)
Interest income	11	4	36	7
Other income (expense), net	10	31	(12)	94
Total other expense:	21	31	23	84
Loss from continuing operations	(182)	(1,250)	(921)	(3,558)
Net loss from discontinued operations		(1,904)		(2,700)
Net loss	(182)	(3,154)	(921)	(6,258)
Less: Undeclared deemed dividend attributable to noncontrolling interest		(77)		(206)
Net loss attributable to Nephros, Inc. shareholders	$ (182)	$ (3,231)	$ (921)	$ (6,464)
Net loss per common share, basic from continuing operations	$ (0.02)	$ (0.12)	$ (0.09)	$ (0.35)
Net loss per common share, diluted from continuing operations	(0.02)	(0.12)	(0.09)	(0.35)
Net loss per common share, basic from discontinued operations		(0.18)		(0.26)
Net loss per common share, diluted from discontinued operations		(0.18)		(0.26)
Net loss per common share, basic	(0.02)	(0.30)	(0.09)	(0.61)
Net loss per common share, diluted	(0.02)	(0.30)	(0.09)	(0.61)
Net loss per common share, basic, attributable to continuing noncontrolling interest		(0.01)		(0.02)
Net loss per common share, diluted, attributable to continuing noncontrolling interest		(0.01)		(0.02)
Net loss per common share, basic, attributable to Nephros, Inc, shareholders	(0.02)	(0.31)	(0.09)	(0.63)
Net loss per common share, diluted, attributable to Nephros, Inc, shareholders	$ (0.02)	$ (0.31)	$ (0.09)	$ (0.63)
Weighted average common shares outstanding, basic	10,460,866	10,303,818	10,352,108	10,278,258
Weighted average common shares outstanding, diluted	10,460,866	10,303,818	10,352,108	10,278,258
Comprehensive loss:
Net loss	$ (182)	$ (3,154)	$ (921)	$ (6,258)
Other comprehensive loss, foreign currency translation adjustments, net of tax				(3)
Comprehensive loss	(182)	(3,154)	(921)	(6,261)
Comprehensive loss attributable to noncontrolling interest		(77)		(206)
Comprehensive loss attributable to Nephros, Inc. shareholders	(182)	(3,231)	(921)	(6,467)
Product [Member]
Net revenue:
Total net revenues	3,713	2,399	10,912	7,387
Royalty and Other Revenues [Member]
Net revenue:
Total net revenues	$ 29	$ 10	$ 72	$ 30

Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Parent [Member]	Noncontrolling Interest [Member]	Total
Beginning balance, value at Dec. 31, 2021	$ 10	$ 147,346	$ 64	$ (135,725)	$ 11,695	$ 3,054	$ 14,749
Balance, shares at Dec. 31, 2021	10,198,712
Net loss				(1,967)	(1,967)		(1,967)
Change in non-controlling interest						188	188
Stock-based compensation		272			272		272
Net unrealized losses on foreign currency translation, net of tax			(3)		(3)		(3)
Exercise of warrants		163			163		163
Exercise of warrants, shares	60,374
Ending balance, value at Mar. 31, 2022	$ 10	147,781	61	(137,692)	10,160	3,242	13,402
Ending balance, shares at Mar. 31, 2022	10,259,086
Beginning balance, value at Dec. 31, 2021	$ 10	147,346	64	(135,725)	11,695	3,054	14,749
Balance, shares at Dec. 31, 2021	10,198,712
Net loss							(6,258)
Net unrealized losses on foreign currency translation, net of tax							(3)
Ending balance, value at Sep. 30, 2022	$ 10	148,275		(141,983)	6,302	3,279	9,581
Ending balance, shares at Sep. 30, 2022	10,303,818
Beginning balance, value at Mar. 31, 2022	$ 10	147,781	61	(137,692)	10,160	3,242	13,402
Balance, shares at Mar. 31, 2022	10,259,086
Net loss				(1,137)	(1,137)		(1,137)
Stock-based compensation		259			259	18	277
Restricted stock vesting
Restricted stock vesting, shares	44,732
Elimination of cumulative translation adjustment, upon closing of wholly owned foreign subsidiary			(61)		(61)		(61)
Ending balance, value at Jun. 30, 2022	$ 10	148,040		(138,829)	9,221	3,260	12,481
Ending balance, shares at Jun. 30, 2022	10,303,818
Net loss				(3,154)	(3,154)		(3,154)
Stock-based compensation		235			235	19	254
Net unrealized losses on foreign currency translation, net of tax
Ending balance, value at Sep. 30, 2022	$ 10	148,275		(141,983)	6,302	3,279	9,581
Ending balance, shares at Sep. 30, 2022	10,303,818
Beginning balance, value at Dec. 31, 2022	$ 10	148,413		(142,831)	5,592	3,289	8,881
Balance, shares at Dec. 31, 2022	10,297,429
Net loss				(306)	(306)		(306)
Change in non-controlling interest		3,262			3,262	(3,262)
Stock-based compensation		346			346	(27)	319
Ending balance, value at Mar. 31, 2023	$ 10	152,021		(143,137)	8,894		8,894
Ending balance, shares at Mar. 31, 2023	10,297,429
Beginning balance, value at Dec. 31, 2022	$ 10	148,413		(142,831)	5,592	3,289	8,881
Balance, shares at Dec. 31, 2022	10,297,429
Net loss							(921)
Net unrealized losses on foreign currency translation, net of tax
Ending balance, value at Sep. 30, 2023	$ 10	152,364		(143,752)	8,622		8,622
Ending balance, shares at Sep. 30, 2023	10,484,932
Beginning balance, value at Mar. 31, 2023	$ 10	152,021		(143,137)	8,894		8,894
Balance, shares at Mar. 31, 2023	10,297,429
Net loss				(433)	(433)		(433)
Stock-based compensation		194			194		194
Ending balance, value at Jun. 30, 2023	$ 10	152,215		(143,570)	8,655		8,655
Ending balance, shares at Jun. 30, 2023	10,297,429
Net loss				(182)	(182)		(182)
Stock-based compensation		149			149		149
Restricted stock vesting
Restricted stock vesting, shares	187,503
Net unrealized losses on foreign currency translation, net of tax
Ending balance, value at Sep. 30, 2023	$ 10	$ 152,364		$ (143,752)	$ 8,622		$ 8,622
Ending balance, shares at Sep. 30, 2023	10,484,932

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
OPERATING ACTIVITIES:
Net loss	$ (921)	$ (6,258)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation of property and equipment	29	82
Amortization of intangible assets, license and supply agreement and finance lease right-of-use asset	134	214
Stock-based compensation, including stock options and restricted stock	662	803
Inventory obsolescence charge	106	773
Provision for bad debt expense	14	(1)
Impairment of assets held for sale		1,395
Gain on foreign currency transactions		(60)
Decrease (increase) in operating assets:
Accounts receivable	(171)	269
Inventory	778	429
Prepaid expenses and other current assets	15	28
Right-of-use assets	234	262
Other assets	(69)	26
(Decrease) increase in operating liabilities:
Accounts payable	65	(555)
Accrued expenses	425	(174)
Lease liabilities	(237)	(272)
Net cash provided by (used in) operating activities	1,064	(3,039)
INVESTING ACTIVITIES:
Purchase of property and equipment		(137)
Net cash used in investing activities		(137)
FINANCING ACTIVITIES:
Proceeds from sale of subsidiary preferred shares to noncontrolling interest		188
Principal payments on finance lease liability	(4)	(3)
Principal payments on equipment financing	(1)	(2)
Payments on secured note payable	(71)	(201)
Proceeds from exercise of warrants		163
Net cash provided by (used in) financing activities	(76)	145
Effect of exchange rates on cash and cash equivalents		(2)
Net increase (decrease) in cash and cash equivalents	988	(3,033)
Cash and cash equivalents, beginning of period	3,634	6,973
Cash and cash equivalents, end of period	4,622	3,940
Supplemental disclosure of cash flow information
Cash paid for interest	6	17
Supplemental disclosure of noncash investing and financing activities
Right-of-use asset obtained in exchange for operating lease liability		$ 69

Organization and Nature of Operations

9 Months Ended

Sep. 30, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Nature of Operations

Note 1 – Organization and Nature of Operations

Basis of Presentation and Liquidity

9 Months Ended

Sep. 30, 2023

Accounting Policies [Abstract]

Basis of Presentation and Liquidity

Note 2 – Basis of Presentation and Liquidity

Interim Financial Information

Segment Reporting

The Company operates in only one business segment from which the Company’s chief operating decision maker evaluates the financial performance of the Company.

Consolidation

Use of Estimates

Liquidity

Recently Adopted Accounting Pronouncements

Concentration of Credit Risk

Major Customers

For the three months ended September 30, 2023, and 2022, the following customers accounted for the following percentages of the Company’s revenues, respectively:

Customer	2023			2022
A		35	%		33	%
B		13	%		4	%
Total		48	%		37	%

For the nine months ended September 30, 2023, and 2022, the following customers accounted for the following percentages of the Company’s revenues, respectively:

Customer	2023			2022
A		24	%		24	%
B		11	%		10	%
Total		35	%		34	%

As of September 30, 2023, and December 31, 2022, the following customers accounted for the following percentages of the Company’s accounts receivable, respectively:

Customer	2023			2022
C		15	%		10	%
A		14	%		21	%
B		4	%		10	%
Total		33	%		41	%

Accounts Receivable

Depreciation Expense

Revenue Recognition

9 Months Ended

Sep. 30, 2023

Revenue from Contract with Customer [Abstract]

Revenue Recognition

Note 3 – Revenue Recognition

Other Revenue – Other revenues are derived from sales of services to customers, which primarily include installation, training and testing on products and equipment sold to certain customers.

Discontinued Operations

9 Months Ended

Sep. 30, 2023

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

Note 4 – Discontinued Operations

All discontinued operations relate to the Company’s previously reported PDS segment, for the three and nine months ended September 30, 2022.

	Three Months Ended			Nine Months Ended
	September 30, 2022			September 30, 2022
		(in thousands)			(in thousands)
Total net revenues	$	79		$	141
Gross loss		(149	)		(211	)
Research and development expenses		192			556
Depreciation and amortization expense		7			21
Selling, general and administrative expenses		161			517
Total operating expenses		360			1,094
Operating loss from discontinued operations		(509	)		(1,305	)
Impairment of assets held for sale		(1,395	)		(1,395	)
Loss from discontinued operations	$	(1,904	)	$	(2,700	)

The following items related to discontinued operations were included in the condensed consolidated statement of cash flows:

	For the nine months ended,
	September 30, 2022
		(in thousands)
Depreciation	$	42
Amortization		82
Stock compensation		66
Impairment of assets held-for-sale		1,395
Operating lease right-of-use assets		33
Purchases of property and equipment		(34	)

Fair Value Measurements

9 Months Ended

Sep. 30, 2023

Fair Value Disclosures [Abstract]

Fair Value Measurements

Note 5 – Fair Value Measurements

The Company measures certain financial instruments and other items at fair value.

To measure fair value, the Company uses the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level of classification for each reporting period.

At September 30, 2023 and December 31, 2022, the fair value measurements of the Company’s assets and liabilities measured on a recurring basis were as follows:

	Fair Value Measurements at Reporting Date Using
	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
	(in thousands)
September 30, 2023
Cash	$	1,320		$		$
Money market funds		1,802
Certificate of deposit		1,500
Cash and cash equivalents	$	4,622	$	-	$	-

December 31, 2022
Cash	$	1,598		$		$
Money market funds		2,036
Cash and cash equivalents	$	3,634	$	-	$	-

Assets and Liabilities Not Measured at Fair Value on a Recurring Basis

The carrying amounts of accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term maturity of these instruments.

Inventory

9 Months Ended

Sep. 30, 2023

Inventory Disclosure [Abstract]

Inventory

Note 6 – Inventory

	September 30, 2023		December 31, 2022
		(in thousands)
Finished goods	$	1,895	$	2,709
Raw materials		373		422
Work in process		-		22
Total inventory	$	2,268	$	3,153

Intangible Assets and Goodwill

9 Months Ended

Sep. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets and Goodwill

Note 7 – Intangible Assets and Goodwill

Intangible Assets

	September 30, 2023							December 31, 2022
	Cost		Accumulated Amortization			Net		Cost		Accumulated Amortization			Net
		(in thousands)
Tradenames, service marks and domain names	$	50	$	(47	)	$	3	$	50	$	(40	)	$	10
Customer relationships		540		(151	)		389		540		(127	)		413
Total intangible assets	$	590	$	(198	)	$	392	$	590	$	(167	)	$	423

As of September 30, 2023, future amortization expense for each of the next five years is (in thousands):

Fiscal Years
2023 (excluding the nine months ended September 30, 2023)	$	11
2024		32
2025		32
2026		32
2027		32
2028		32

Goodwill

Goodwill has a carrying value on the Company’s consolidated balance sheets of approximately $0.8 million at September 30, 2023 and December 31, 2022.

License and Supply Agreement, net

9 Months Ended

Sep. 30, 2023

License And Supply Agreement Net

License and Supply Agreement, net

Note 8 – License and Supply Agreement, net

Secured Note Payable

9 Months Ended

Sep. 30, 2023

Debt Disclosure [Abstract]

Secured Note Payable

Note 9 – Secured Note Payable

Leases

9 Months Ended

Sep. 30, 2023

Leases

Leases

Note 10 – Leases

The Company has operating leases for corporate offices, an automobile and office equipment. The leases have remaining lease terms of 1 year to 5 years.

Lease cost, as presented below, includes costs associated with leases for which right-of-use (“ROU”) assets have been recognized as well as short-term leases.

The components of total lease costs were as follows:

		Three months ended September 30, 2023		Three months ended September 30, 2022
	(in thousands)
Operating lease cost		$	90	$	103
Finance lease cost:
Amortization of right-of-use assets			2		2
Interest on lease liabilities			-		1
Total finance lease cost			2		3
Variable lease cost			2		9
Total lease cost		$	94	$	115

	Nine months ended September 30, 2023		Nine months ended September 30, 2022
	(in thousands)
Operating lease cost	$	272	$	316
Finance lease cost:
Amortization of right-of-use assets		6		7
Interest on lease liabilities		2		4
Total finance lease cost		8		11
Variable lease cost		9		28
Total lease cost	$	289	$	355

Supplemental cash flow information related to leases was as follows:

	Nine months ended September 30, 2023		Nine months ended September 30, 2022
	(in thousands)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	272	$	316
Financing cash flows from finance leases	$	4	$	3

Supplemental balance sheet information related to leases was as follows:

	September 30, 2023			December 31, 2022
	(in thousands)
Operating lease right-of-use assets	$	744		$	972
Finance lease right-of-use assets	$	6		$	12

Current portion of operating lease liabilities	$	305		$	309
Operating lease liabilities, net of current portion		469			700
Total operating lease liabilities	$	774		$	1,009

Current portion of finance lease liabilities	$	6		$	8
Finance lease liabilities, net of current portion		-			4
Total finance lease liabilities	$	6		$	12

Weighted average remaining lease term
Operating leases		3.4 years			3.9 years
Finance leases		0.8 years			1.5 years

Weighted average discount rate
Operating leases		8.0	%		8.0	%
Finance leases		8.0	%		8.0	%

As of September 30, 2023, maturities of lease liabilities were as follows:

	Operating Leases			Finance Leases
	(in thousands)
2023 (excluding the nine months ended September 30, 2023)	$	53		$	2
2024		299			4
2025		163			-
2026		168			-
2027		158			-
Total future minimum lease payments		841			6
Less imputed interest		(67	)		-
Total	$	774		$	6

Stock Plans and Share-Based Payments

9 Months Ended

Sep. 30, 2023

Share-Based Payment Arrangement [Abstract]

Stock Plans and Share-Based Payments

Note 11 – Stock Plans and Share-Based Payments

Stock Options

Assumptions for Option Grants
Stock Price Volatility	74.03	%
Risk-Free Interest Rate	3.44	%
Expected Life (in years)	6.21
Expected Dividend Yield	-	%

Restricted Stock

As of September 30, 2023, there was no unrecognized compensation expense related to unvested stock-based awards granted under the equity compensation plans.

SRP Equity Incentive Plan

Stockholders’ Equity

9 Months Ended

Sep. 30, 2023

Equity [Abstract]

Stockholders’ Equity

Note 12 – Stockholders’ Equity

Noncontrolling Interest

Warrants

During the three and nine months ended September 30, 2023, the Company had no outstanding warrants.

Net Loss per Common Share

9 Months Ended

Sep. 30, 2023

Earnings Per Share [Abstract]

Net Loss per Common Share

Note 13 – Net Loss per Common Share

The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as they would be antidilutive:

	September 30,
	2023		2022
Shares underlying options outstanding		1,767,443		1,492,247

Commitments and Contingencies

9 Months Ended

Sep. 30, 2023

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 14 – Commitments and Contingencies

Purchase Commitments

Contractual Obligations

See Note 10 – Leases for a discussion of the Company’s contractual obligations.

Basis of Presentation and Liquidity (Policies)

9 Months Ended

Sep. 30, 2023

Accounting Policies [Abstract]

Interim Financial Information

Interim Financial Information

Segment Reporting

Segment Reporting

The Company operates in only one business segment from which the Company’s chief operating decision maker evaluates the financial performance of the Company.

Consolidation

Consolidation

Use of Estimates

Use of Estimates

Liquidity

Liquidity

Recently Adopted Accounting Pronouncements

Recently Adopted Accounting Pronouncements

Concentration of Credit Risk

Concentration of Credit Risk

Major Customers

Major Customers

For the three months ended September 30, 2023, and 2022, the following customers accounted for the following percentages of the Company’s revenues, respectively:

Customer	2023			2022
A		35	%		33	%
B		13	%		4	%
Total		48	%		37	%

For the nine months ended September 30, 2023, and 2022, the following customers accounted for the following percentages of the Company’s revenues, respectively:

Customer	2023			2022
A		24	%		24	%
B		11	%		10	%
Total		35	%		34	%

As of September 30, 2023, and December 31, 2022, the following customers accounted for the following percentages of the Company’s accounts receivable, respectively:

Customer	2023			2022
C		15	%		10	%
A		14	%		21	%
B		4	%		10	%
Total		33	%		41	%

Accounts Receivable

Accounts Receivable

Depreciation Expense

Depreciation Expense

Basis of Presentation and Liquidity (Tables)

9 Months Ended

Sep. 30, 2023

Accounting Policies [Abstract]

Schedule of Revenues and Accounts Receivable Percentage of Major Customers

For the three months ended September 30, 2023, and 2022, the following customers accounted for the following percentages of the Company’s revenues, respectively:

Customer	2023			2022
A		35	%		33	%
B		13	%		4	%
Total		48	%		37	%

For the nine months ended September 30, 2023, and 2022, the following customers accounted for the following percentages of the Company’s revenues, respectively:

Customer	2023			2022
A		24	%		24	%
B		11	%		10	%
Total		35	%		34	%

As of September 30, 2023, and December 31, 2022, the following customers accounted for the following percentages of the Company’s accounts receivable, respectively:

Customer	2023			2022
C		15	%		10	%
A		14	%		21	%
B		4	%		10	%
Total		33	%		41	%

Discontinued Operations (Tables)

9 Months Ended

Sep. 30, 2023

Discontinued Operations and Disposal Groups [Abstract]

Schedule of Assets and Liabilities of Discontinued Operations

All discontinued operations relate to the Company’s previously reported PDS segment, for the three and nine months ended September 30, 2022.

	Three Months Ended			Nine Months Ended
	September 30, 2022			September 30, 2022
		(in thousands)			(in thousands)
Total net revenues	$	79		$	141
Gross loss		(149	)		(211	)
Research and development expenses		192			556
Depreciation and amortization expense		7			21
Selling, general and administrative expenses		161			517
Total operating expenses		360			1,094
Operating loss from discontinued operations		(509	)		(1,305	)
Impairment of assets held for sale		(1,395	)		(1,395	)
Loss from discontinued operations	$	(1,904	)	$	(2,700	)

The following items related to discontinued operations were included in the condensed consolidated statement of cash flows:

	For the nine months ended,
	September 30, 2022
		(in thousands)
Depreciation	$	42
Amortization		82
Stock compensation		66
Impairment of assets held-for-sale		1,395
Operating lease right-of-use assets		33
Purchases of property and equipment		(34	)

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2023

Fair Value Disclosures [Abstract]

Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis

At September 30, 2023 and December 31, 2022, the fair value measurements of the Company’s assets and liabilities measured on a recurring basis were as follows:

	Fair Value Measurements at Reporting Date Using
	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
	(in thousands)
September 30, 2023
Cash	$	1,320		$		$
Money market funds		1,802
Certificate of deposit		1,500
Cash and cash equivalents	$	4,622	$	-	$	-

December 31, 2022
Cash	$	1,598		$		$
Money market funds		2,036
Cash and cash equivalents	$	3,634	$	-	$	-

Inventory (Tables)

9 Months Ended

Sep. 30, 2023

Inventory Disclosure [Abstract]

Schedule of Inventory, Net

	September 30, 2023		December 31, 2022
		(in thousands)
Finished goods	$	1,895	$	2,709
Raw materials		373		422
Work in process		-		22
Total inventory	$	2,268	$	3,153

Intangible Assets and Goodwill (Tables)

9 Months Ended

Sep. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets

	September 30, 2023							December 31, 2022
	Cost		Accumulated Amortization			Net		Cost		Accumulated Amortization			Net
		(in thousands)
Tradenames, service marks and domain names	$	50	$	(47	)	$	3	$	50	$	(40	)	$	10
Customer relationships		540		(151	)		389		540		(127	)		413
Total intangible assets	$	590	$	(198	)	$	392	$	590	$	(167	)	$	423

Schedule of Future Amortization Expense

As of September 30, 2023, future amortization expense for each of the next five years is (in thousands):

Fiscal Years
2023 (excluding the nine months ended September 30, 2023)	$	11
2024		32
2025		32
2026		32
2027		32
2028		32

Leases (Tables)

9 Months Ended

Sep. 30, 2023

Leases

Schedule of Components of Lease Cost

The components of total lease costs were as follows:

		Three months ended September 30, 2023		Three months ended September 30, 2022
	(in thousands)
Operating lease cost		$	90	$	103
Finance lease cost:
Amortization of right-of-use assets			2		2
Interest on lease liabilities			-		1
Total finance lease cost			2		3
Variable lease cost			2		9
Total lease cost		$	94	$	115

	Nine months ended September 30, 2023		Nine months ended September 30, 2022
	(in thousands)
Operating lease cost	$	272	$	316
Finance lease cost:
Amortization of right-of-use assets		6		7
Interest on lease liabilities		2		4
Total finance lease cost		8		11
Variable lease cost		9		28
Total lease cost	$	289	$	355

Schedule of Supplemental Cash Flow Information Related to Leases

Supplemental cash flow information related to leases was as follows:

	Nine months ended September 30, 2023		Nine months ended September 30, 2022
	(in thousands)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	272	$	316
Financing cash flows from finance leases	$	4	$	3

Schedule of Supplemental Balance Sheet Information Related to Leases

Supplemental balance sheet information related to leases was as follows:

	September 30, 2023			December 31, 2022
	(in thousands)
Operating lease right-of-use assets	$	744		$	972
Finance lease right-of-use assets	$	6		$	12

Current portion of operating lease liabilities	$	305		$	309
Operating lease liabilities, net of current portion		469			700
Total operating lease liabilities	$	774		$	1,009

Current portion of finance lease liabilities	$	6		$	8
Finance lease liabilities, net of current portion		-			4
Total finance lease liabilities	$	6		$	12

Weighted average remaining lease term
Operating leases		3.4 years			3.9 years
Finance leases		0.8 years			1.5 years

Weighted average discount rate
Operating leases		8.0	%		8.0	%
Finance leases		8.0	%		8.0	%

Schedule of Maturities of Lease Liabilities

As of September 30, 2023, maturities of lease liabilities were as follows:

	Operating Leases			Finance Leases
	(in thousands)
2023 (excluding the nine months ended September 30, 2023)	$	53		$	2
2024		299			4
2025		163			-
2026		168			-
2027		158			-
Total future minimum lease payments		841			6
Less imputed interest		(67	)		-
Total	$	774		$	6

Stock Plans and Share-Based Payments (Tables)

9 Months Ended

Sep. 30, 2023

Share-Based Payment Arrangement [Abstract]

Schedule of Fair Value Assumptions

Assumptions for Option Grants
Stock Price Volatility	74.03	%
Risk-Free Interest Rate	3.44	%
Expected Life (in years)	6.21
Expected Dividend Yield	-	%

Net Loss per Common Share (Tables)

9 Months Ended

Sep. 30, 2023

Earnings Per Share [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as they would be antidilutive:

	September 30,
	2023		2022
Shares underlying options outstanding		1,767,443		1,492,247

Schedule of Revenues and Accounts Receivable Percentage of Major Customers (Details) - Customer Concentration Risk [Member]	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Customer A [Member] \| Revenue Benchmark [Member]
Product Information [Line Items]
Total	35.00%	33.00%	24.00%	24.00%
Customer A [Member] \| Accounts Receivable [Member]
Product Information [Line Items]
Total			14.00%		21.00%
Customer B [Member] \| Revenue Benchmark [Member]
Product Information [Line Items]
Total	13.00%	4.00%	11.00%	10.00%
Customer B [Member] \| Accounts Receivable [Member]
Product Information [Line Items]
Total			4.00%		10.00%
Customer Total [Member] \| Revenue Benchmark [Member]
Product Information [Line Items]
Total	48.00%	37.00%	35.00%	34.00%
Customer Total [Member] \| Accounts Receivable [Member]
Product Information [Line Items]
Total			33.00%		41.00%
Customer C [Member] \| Accounts Receivable [Member]
Product Information [Line Items]
Total			15.00%		10.00%

Basis of Presentation and Liquidity (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Feb. 28, 2022	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2020	Dec. 31, 2022
Retained earnings (accumulated deficit)		$ 143,752,000		$ 143,752,000			$ 142,831,000
Net cash provided by (used in) operating activities				1,064,000	$ (3,039,000)
Allowance for doubtful accounts receivable		14,000		14,000			$ 0
Depreciation expense		1,000	$ 3,000	3,000	$ 19,000
Specialty Renal Products, Inc. [Member] \| Loan Agreement [Member]
Repayments of debt						$ 1,300,000
Proceeds from loans						$ 1,000,000.0
Loans payable		$ 0		$ 0
Specialty Renal Products, Inc. [Member] \| Series A Preferred Stock [Member] \| SRP Purchase Agreement [Member]
Number of shares sold in transaction	100,003
Share price	$ 5.00
Gross proceeds received through transaction	$ 500,015

Revenue Recognition (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Total net revenues	$ 3,742	$ 2,409	$ 10,984	$ 7,417
Royalty and Other Revenues [Member]
Disaggregation of Revenue [Line Items]
Total net revenues	$ 29	$ 10	$ 72	$ 30

Schedule of Assets and Liabilities of Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Discontinued Operations and Disposal Groups [Abstract]
Total net revenues		$ 79		$ 141
Gross loss		(149)		(211)
Research and development expenses		192		556
Depreciation and amortization expense		7		21
Selling, general and administrative expenses		161		517
Total operating expenses		360		1,094
Operating loss from discontinued operations		(509)		(1,305)
Impairment of assets held for sale		(1,395)		(1,395)
Loss from discontinued operations		$ (1,904)		(2,700)
Depreciation				42
Amortization				82
Stock compensation				66
Impairment of assets held-for-sale				1,395
Operating lease right-of-use assets				33
Purchases of property and equipment				$ (34)

Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash	$ 1,320	$ 1,598
Money market funds	1,802	2,036
Certificate of deposit	1,500
Cash and cash equivalents	4,622	3,634
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents

Schedule of Inventory, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Finished goods	$ 1,895	$ 2,709
Raw materials	373	422
Work in process		22
Total inventory	$ 2,268	$ 3,153

Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 590	$ 590
Accumulated Amortization	(198)	(167)
Total Intangible Assets, Net	392	423
Tradenames, Service Marks and Domain Names [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	50	50
Accumulated Amortization	(47)	(40)
Total Intangible Assets, Net	3	10
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	540	540
Accumulated Amortization	(151)	(127)
Total Intangible Assets, Net	$ 389	$ 413

Schedule of Future Amortization Expense (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2023 (excluding the nine months ended September 30, 2023)	$ 11
2024	32
2025	32
2026	32
2027	32
2028	$ 32

Intangible Assets and Goodwill (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 11	$ 11	$ 31	$ 31
Intangible asset impairment charges		$ 1,000		$ 1,000
Goodwill	$ 759		$ 759		$ 759

License and Supply Agreement, net (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Sep. 30, 2013
Gross value of intangible asset capitalized	$ 2,300,000		$ 2,300,000
Licence agreements,net	301,000		301,000		$ 402,000
Accumulated Amortization	(198,000)		(198,000)		(167,000)
Amortization of intangible assets	11,000	$ 11,000	31,000	$ 31,000
Accounts Payable [Member]
Royalty expense			102,000		71,000
Cost of Goods Sold [Member]
Royalty expense	102,000	64,000	292,000	198,000
Medica [Member]
Debt instrument, interest rate, stated percentage						12.00%
License and Supply Agreement [Member]
Accumulated Amortization	2,000,000		2,000,000		$ 1,900,000
Amortization of intangible assets	$ 33,000	$ 33,000
Interest expense, debt			$ 0	$ 0
License and Supply Agreement [Member] \| Medica [Member] \| April 23, 2014 through December 31, 2025 [Member]
Royalty rate			3.00%

Secured Note Payable (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
Secured Note Payable (Details Narrative) - USD ($)	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Mar. 27, 2018
Short-Term Debt [Line Items]
Interest expense		$ 4,000	$ 1,000	$ 17,000
Secured Note [Member]
Short-Term Debt [Line Items]
Repayments of notes payable		72,000	71,000	216,000
Interest expense		$ 4,000	$ 1,000	$ 15,000
Secured Promissory Note Agreement [Member] \| Tech Capital, LLC [Member]
Short-Term Debt [Line Items]
Principal amount of secured note payable					$ 1,200,000
Maturity date			Apr. 01, 2023
Debt interest rate	8.00%		8.00%
Maturity date, description			Principal and interest payments were due on the first day of each month commencing on May 1, 2018

Schedule of Components of Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Leases
Operating lease cost	$ 90	$ 103	$ 272	$ 316
Finance lease cost:
Amortization of right-of-use assets	2	2	6	7
Interest on lease liabilities		1	2	4
Total finance lease cost	2	3	8	11
Variable lease cost	2	9	9	28
Total lease cost	$ 94	$ 115	$ 289	$ 355

Schedule of Supplemental Cash Flow Information Related to Leases (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 272	$ 316
Financing cash flows from finance leases	$ 4	$ 3

Schedule of Supplemental Balance Sheet Information Related to Leases (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Leases
Operating lease right-of-use assets	$ 744	$ 972
Finance lease right-of-use assets	6	12
Current portion of operating lease liabilities	305	309
Operating lease liabilities, net of current portion	469	700
Total operating lease liabilities	774	1,009
Current portion of finance lease liabilities	6	8
Finance lease liabilities, net of current portion		4
Total finance lease liabilities	$ 6	$ 12
Weighted average remaining lease term, Operating leases	3 years 4 months 24 days	3 years 10 months 24 days
Weighted average remaining lease term, Finance leases	9 months 18 days	1 year 6 months
Operating leases	8.00%	8.00%
Finance leases	8.00%	8.00%

Schedule of Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]
Operating Leases, 2023	$ 53
Operating Leases, 2024	299
Operating Leases, 2025	163
Operating Leases, 2026	168
Operating Leases, 2027	158
Operating Leases, Total future minimum lease payments	841
Operating Leases, Less imputed interest	(67)
Operating Leases, Total	774	$ 1,009
Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]
Finance Leases, 2023	2
Finance Leases, 2024	4
Finance Leases, 2025
Finance Leases, 2026
Finance Leases, 2027
Finance Leases, Total future minimum lease payments	6
Finance Leases, Less imputed interest
Finance Leases, Total	$ 6	$ 12

Leases (Details Narrative)	Sep. 30, 2023
Minimum [Member]
Operating lease term	1 year
Maximum [Member]
Operating lease term	5 years

Schedule of Fair Value Assumptions (Details) - Employee Stock [Member]	9 Months Ended
	Sep. 30, 2023
Subsidiary, Sale of Stock [Line Items]
Stock Price Volatility	74.03%
Risk-Free Interest Rates	3.44%
Expected Life (in years)	6 years 2 months 15 days
Expected Dividend Yield

Stock Plans and Share-Based Payments (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	May 07, 2019
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Income tax benefit	$ 0	$ 0	$ 0	$ 0
Unrecognized compensation expense	819,000		$ 819,000
Unrecognized compensation expense, period for recognition			2 years 4 months 24 days
SRP Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expense		19,000	$ (27,000)	37,000
Number of shares reserved and authorized for awards					150,000
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expense	137,000	251,000	486,000	724,000
Share-Based Payment Arrangement, Option [Member] \| Selling, General and Administrative Expenses [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expense	134,000	227,000	450,000	669,000
Share-Based Payment Arrangement, Option [Member] \| Research and Development Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expense	3,000	24,000	36,000	55,000
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expense	12,000		$ 49,000	42,000
credit of expense due to forfeiture		(16,000)
Forfeiture of unvested restricted stock		16,000
Vesting period			6 months
Restricted Stock [Member] \| Selling, General and Administrative Expenses [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expense		(16,000)	$ 49,000	$ 42,000
Unvested Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
credit of expense due to forfeiture		(15,000)
Forfeiture of unvested restricted stock		$ 15,000
Unrecognized compensation expense	$ 0		$ 0
Employees [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock options granted	6,000		453,065
Fair value of stock options granted	$ 400,000		$ 400,000
Employees [Member] \| Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares issued			23,781
Board [Member] \| Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares issued			133,722
Contractors [Member] \| Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares issued			30,000

Stockholders’ Equity (Details Narrative) - USD ($)				1 Months Ended		3 Months Ended	9 Months Ended		12 Months Ended
Stockholders’ Equity (Details Narrative) - USD ($)	Feb. 04, 2022	Feb. 01, 2022	Sep. 09, 2018	Mar. 31, 2023	Feb. 28, 2022	Mar. 31, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2020
Class of Stock [Line Items]
Inventory write down							$ 106,000	$ 773,000
Proceeds from warrants exercised								$ 163,000
Warrant [Member]
Class of Stock [Line Items]
Warrants outstanding							0
Warrants to purchase common stock exercised								60,374
Proceeds from warrants exercised								$ 200,000
Number of warrant expired								63,102
Management [Member] \| Warrant [Member]
Class of Stock [Line Items]
Warrants to purchase common stock exercised								14,815
Proceeds from warrants exercised								$ 40,000
Specialty Renal Products, Inc. [Member]
Class of Stock [Line Items]
Outstanding indebtness				$ 1,500,000
Inventory write down						$ 24,000,000
Specialty Renal Products, Inc. [Member] \| Chief Executive Officer [Member]
Class of Stock [Line Items]
Number of shares issued for common stock					313
Specialty Renal Products, Inc. [Member]
Class of Stock [Line Items]
Number of shares issued for common stock					62,500
Ownership percentage					62.50%
Specialty Renal Products, Inc. [Member] \| Lambda Investors LLC [Member] \| Series A Preferred Stock [Member]
Class of Stock [Line Items]
Number of shares issued for common stock					25,938
Ownership percentage					36.00%
Series A Preferred Stock Purchase Agreement [Member]
Class of Stock [Line Items]
Sale of stock			600,000
Sale of stock price per share			$ 5.00
Proceeds from sale of stock			$ 3,000,000.0
SRP Purchase Agreement Closing [Member]
Class of Stock [Line Items]
Sale of stock		100,003
Proceeds from sale of stock	$ 500,015
Sale of stock					$ 188,000
Loan Agreement [Member] \| Specialty Renal Products, Inc. [Member]
Class of Stock [Line Items]
Repayments of debt									$ 1,300,000
Proceeds from Loans									$ 1,000,000.0

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	1,767,443	1,492,247

Commitments and Contingencies (Details Narrative) - License and Supply Agreement [Member] - Medica Spa [Member] € in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2023 USD ($)	Dec. 31, 2023 EUR (€)	Sep. 30, 2023 USD ($)	Sep. 30, 2023 EUR (€)
Purchase commitment, minimum amount committed			$ 4.8	€ 4.5
Forecast [Member]
Long-term purchase commitment, amount	$ 4.1	€ 3.8